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Résumé 
Le fer, un métal de transition, est requis pour la survie de presque tout les organismes vivant à 
cause de son habilité à accepter ou donner un électron et donc à catalyser plusieurs réactions 
biochimique fondamentales. Cependant, la même propriété permet aussi au fer ionique 
d’accélérer la formation de radicaux libres et donc le fer peut potentiellement avoir des effets 
néfastes. Conséquemment, l’homéostasie du fer doit être étroitement régulé, tant au niveau 
cellulaire que systémique. Notre étude met l’emphase sur deux molécules importante pour 
régulation du métabolisme du fer : la lipocaline 2 (Lcn2) et l’hepcidine.  
 
Lcn2, une protéine de phase aiguë, est impliquée dans le transport du fer par les sidérophores. 
Lcn2 est un candidat potentiel comme transporteur du fer qui pourrait être responsable de 
l’accumulation excessive du fer non lié à la transferrine dans le foie des patients atteints 
d’hémochromatose héréditaire (HH). Nous avons généré des souris double-déficiente HfeLcn2 
pour évaluer l’importance de Lcn2 dans la pathogenèse de surcharge en fer hépatique dans les 
souris knock-out Hfe (Hfe 
-/-
). Notre étude révèle que la délétion de Lcn2 dans les souris Hfe
-/-
 
n’influence pas leur accumulation de fer hépatique ou leur réponse à une surcharge en fer. Le 
phénotype des souries HfeLcn2
-/-
 demeure indiscernable de celui des souris Hfe
-/-
. Nos données 
impliquent que Lcn2 n’est pas essentiel pour la livraison du fer aux hépatocytes dans l’HH.   
 
L’hepcidine, un régulateur clé du métabolisme du fer, est un petit peptide antimicrobien 
produit par le foie et qui régule l’absorption intestinale du fer et son recyclage par les 
macrophages. L’expression de l’hepcidine est induite par la surcharge en fer et l’inflammation, 
tandis que, à l'inverse, elle est inhibée par l'anémie et l'hypoxie. Dans certaine situations 
pathologique, l’hepcidine est régulée dans des directions opposées par plus d’un régulateur. 
Nous avons, en outre, analysé comment les différents facteurs influencent l’expression de 
l’hepcidine in vivo en utilisant un modèle de souris avec un métabolisme du fer altéré. Nous 
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avons examiné la régulation de l’hepcidine en présence de stimuli opposés, ainsi que la 
contribution des médiateurs et des voix de signalisation  en aval de l’expression de 
l’hepcidine. Nous avons démontré que l'érythropoïèse, lorsque stimulé par l’érythropoïétine, 
mais pas par l’hypoxie, diminue l’expression de l’hepcidine d’une façon dépendante de la dose, 
même en présence de lipopolysaccharides ou de surcharge de fer alimentaire, qui peuvent agir 
de manière additive. De plus, l’entraînement érythropoïétique inhibe tant la voix 
inflammatoire que celle de détection du fer, du moins en partie, par la suppression du signal 
IL-6/STAT3 et BMP/SMAD4 in vivo. Au total, nos données suggèrent que le niveau 
d’expression de l’hepcidine en présence de signaux opposés est déterminé par la force du 
stimulus individuel plutôt que par une hiérarchie absolue. Ces découvertes sont pertinentes 
pour le traitement de l’anémie des maladies chronique et les désordres de surcharge en fer.  
 
 
 
Mots-clés : Fer, système immunitaire, hepcidine, lipocaline 2, BMP, SMAD, STAT3 
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Abstract 
 
Iron, a transition metal, is required for survival by almost all living organisms due to its ability 
to accept or donate electrons and thus to catalyze many fundamental biochemical reactions. 
However, the same properties also allow ionic iron to accelerate the formation of free radicals 
and as such iron has the potential for deleterious effects. Consequently, iron homeostasis must 
be tightly regulated at both cellular and systemic levels. Our studies focused on two important 
molecules in the regulation of iron metabolism, namely, lipocalin 2 (Lcn2) and hepcidin.  
 
Lcn2, an acute phase protein, is involved in iron trafficking via siderophores. Lcn2 has 
emerged as a candidate iron-transporter that may be responsible for excessive 
non-transferrin-bound iron (NTBI) accumulation in the liver of hereditary hemochromatosis 
(HH) patients. We generated HfeLcn2 double-deficient mice to evaluate the importance of Lcn2 
in the pathogenesis of hepatic iron loading in Hfe knockout
 
mice. Our studies revealed that 
deletion of Lcn2 in Hfe-knockout mice does not influence hepatic iron accumulation in Hfe
-/-
 
mice, or their response to iron loading, as the phenotype of HfeLcn2
-/-
 mice remained 
indistinguishable from that of Hfe
-/-
 mice. Our data imply that Lcn2 is not essential for iron 
delivery to hepatocytes in HH. 
 
Hepcidin, a key regulator of iron metabolism, is a small antimicrobial peptide produced by 
the liver that regulates intestinal iron absorption and iron recycling by macrophages. Hepcidin 
expression is induced by iron-loading and inflammation while, conversely, being inhibited by 
anemia and hypoxia. Under certain pathologic situations, hepcidin is regulated in opposite 
directions by more than one regulator. We further investigated how different factors influence 
hepcidin expression in vivo using mouse models of altered iron metabolism. We examined 
hepcidin regulation in the presence of opposing stimuli as well as the contributions of 
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mediators and downstream signaling pathways of hepcidin expression. We show that 
erythropoiesis drive, when stimulated by erythropoietin but not by hypoxia, down-regulates 
hepcidin in a dose-dependent manner, even in the presence of lipopolysaccharide or dietary 
iron-loading, which may act additively. Moreover, erythropoietic drive inhibited both the 
inflammatory and iron-sensing pathways, at least in part, via the suppression of IL-6/STAT3 
and BMP/SMAD4 signaling in vivo. Altogether, our data suggest that hepcidin expression 
levels in the presence of opposing signaling are determined by the strength of the individual 
stimuli rather than by an absolute hierarchy. These findings are pertinent for the treatment of 
the anemia of chronic disease and iron-loading disorders. 
 
 
Keywords: iron, immune system, hepcidin, lipocalin 2, BMP, SMAD, STAT3,  
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CHAPTER 1   INTRODUCTION 
 
 
 
Iron, a transition metal, is required for survival by almost all living organisms due to its ability 
to switch between two different redox states and as such catalyze many fundamental 
biochemical reactions. However, ionic iron can accelerate the formation of free radicals and as 
such has a potential for deleterious effects. Therefore, iron levels need to be tightly regulated 
such as to meet body iron needs, while at the same time avoiding toxicity. The importance of 
iron in biological systems is best illustrated by the ever-increasing number of diseases 
associated with deregulated iron metabolism. Thus, understanding the mechanisms for the 
regulation of iron homeostasis is essential for human health. 
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1. The importance of iron for biological systems 
 
Iron is the fourth most abundant element on the surface of our planet [1]. Despite this relative 
abundance in the rocks constituting the earth's crust, iron is present in rather small quantities in 
living matter. However, iron remains an essential part in many metabolic processes essential 
for life. 
The metabolic importance of this element comes from its chemical properties, as iron can form 
up to six coordination bonds by accepting an electron pair on each of its six atomic orbitals. 
Electronegative elements such as oxygen, nitrogen and sulfur thus have the ability to bind iron. 
This fundamental property allows iron to associate with many biologically-relevant proteins. 
Furthermore, as a transition metal, iron can exist in two forms, the reduced (Fe
2+
, ferrous iron) 
and oxidized forms (Fe
3+
, ferric iron). This ability to alternatively accept and give electrons 
makes iron the cofactor of choice for many redox enzymatic reactions (Figure 1). Therefore, 
the widespread use of iron can be accounted for by its ability to shuttle electrons, flexibility for 
binding ligands in diverse orientations, and its high bioavailability during the early stages of 
evolution under the reducing conditions of a sulphur-rich atmosphere.  
 
1.1 Iron-containing proteins 
Many proteins that have crucial roles in cellular physiology require iron to function. 
Interestingly, most iron-binding proteins are highly conserved across prokaryotes and 
eukaryotes, and the central position of iron in cellular metabolism is maintained in almost all 
forms of life. Depending on how the metal is bound to the protein, iron-containing proteins 
can be classified into three classes: hemoproteins, iron-sulfur proteins and iron-binding 
proteins. 
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1.1.1 Hemoproteins  
Hemoproteins have a tetrapyrrole core at the center of which is encased an iron atom. When 
the iron atom is in the reduced form, the prosthetic group is called heme, whereas it is called 
hemin when the iron atom is in the ferric form [2]. The most representative hemoproteins 
include hemoglobin (Hb), myoglobin [3], cytochromes [4], catalases and peroxidases. 
Hemoglobin and myoglobin are responsible for stabilizing, transporting and storing oxygen. 
Oxygen transport through hemoglobin is one of the most important biological functions of 
iron. Cytochromes constitute major components of the mitochondrial electron transport chains 
(cytochromes a, b, c) that participate in electron transport and energy metabolism [5], while 
catalases and peroxidases are hemoproteins that play a fundamental role in the elimination of 
hazardous reactive oxygen species (ROS) and as such have antioxidant functions.  
 
1.1.2 Iron-sulfur proteins  
This type of protein contains what is called an iron-sulfur center (or cluster) consisting of 
combinations between iron and sulfur atoms of variable stoichiometry. Iron atoms bridge with 
inorganic sulfides and are bound to proteins through cysteine residues to form the iron-sulfur 
(Fe-S) proteins [6]. [2Fe-2S], [4Fe-4S] and [3Fe-4S] are the most common cluster variants in 
eukaryotes [7]. Iron-sulfur proteins include ferredoxins, NADH dehydrogenases, hydrogenases, 
cytochrome c reductase and nitrogenases. They play a critical role in a wide range of cellular 
activities as components of the respiratory electron transport complexes, and of tricarboxylic 
acid cycle enzymes, aconitase and succinate dehydrogenase [7, 8]. In addition, Fe-S clusters 
are components of DNA repair enzymes fundamental for the recognition of DNA damage and 
repair.  
 
1.1.3 Iron-binding proteins 
This class of proteins is characterized by the presence of iron directly associated to the protein. 
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Examples of iron-binding proteins include ribonucleotide reductase necessary during the S 
phase of DNA synthesis, and lipoxygenases that catalyze the oxidation of fatty acids. Other 
iron-binding proteins are fundamental for the transport and storage of iron, namely transferrin 
and ferritin. 
 
 
 
 
 
 
Figure 1 The importance of iron for biological systems  
Iron is vital for almost all living organisms due to participation in a wide variety of cellular 
processes such as cellular respiration, proliferation, detoxification and differentiation [9-13].  
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1.2 Iron toxicity 
 
Although iron is indispensable for life, it may also become toxic. The toxicity of iron is mainly 
associated with its potential participation in the excessive production of ROS, a byproduct of 
oxygen metabolism that describes a variety of molecules and free radicals (chemical species 
with one unpaired electron).  
 
Under normal physiological conditions, superoxide anion (O2
●-
) and hydrogen peroxide (H2O2) 
are continuously produced in tissue cells as byproducts of aerobic metabolism [14, 15]. More 
than 500 liters of oxygen is utilized daily by tissue cells of a normal human subject, and 1-5% 
of the oxygen consumed by the respiratory chain is incompletely reduced to O2
●-
 and H2O2 [14, 
16]. If not efficiently removed, hydroxyl radical (
●
HO) may be generated from H2O2 via the 
Fenton reaction in the presence of Fe
2+
 and cause oxidative damage to cellular components, 
including nucleic acids [17], proteins [18] and lipids [19] . 
 
To cope with the oxidative stress elicited by aerobic metabolism, mammalian cells have 
developed an ubiquitous antioxidant defense system, which consists of superoxide dismutases 
(SODs), catalase, glutathione peroxidases (GPxs) and glutathione reductase together with a 
number of low molecular weight antioxidants such as ascorbate, α-tocopherol and glutathione 
[20, 21] (Figure 2). However, this antioxidant defense system may be overwhelmed by 
various pathological or environmental factors so that a fraction of ROS may escape destruction 
and form the far more reactive hydroxyl radical (
●
HO) [20, 21]. An increase in ROS-elicited 
oxidative damage to DNA and other biomolecules may impair normal functions of tissue cells 
and lead to human aging and disease [17, 20].  
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Because of its destructive potential, iron is suspected to play a role in many pathological 
conditions, including carcinogenesis, atherosclerosis, and a number of neurodegenerative 
disorders, such as Parkinson's or Alzheimer's disease [22-27]. To minimize these potential 
toxic effects, highly sophisticated mechanisms and specialized molecules for the acquisition, 
transport, and storage of iron in soluble, non-toxic forms have evolved to meet cellular iron 
requirements and to systemically-regulate iron homeostasis. 
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Figure 2 The basis for iron toxicity.   
The Haber-Weiss reaction refers to the net reaction (•O2
-
 + H2O2 → •OH + OH
-
 +O2).The 
reaction generates hydroxyl radical (•OH) from hydrogen peroxide (H2O2) and is catalyzed by 
iron. The first step involves reduction of ferric iron to ferrous (Fe
3+
 + •O2
−
 → Fe2+ + O2). The 
second step is the Fenton reaction (Fe
2+
 + H2O2 → Fe
3+
 + OH
−
 + •OH). The highly reactive 
hydroxyl radical (•OH) can lead to oxidative stress-induced protein oxidation, lipid 
peroxidation, mitochondrial dysfunction, and DNA damage. SOD - superoxide dismutase; 
GPx – glutathione peroxidase. 
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2. Iron homeostasis  
 
The chemical properties of iron place two limitations on the biological behavior of this element. 
First, although iron is abundant, the metal is most commonly found in nature as the insoluble 
ferric hydroxide. Therefore, organisms have evolved complex mechanisms to obtain iron from 
their environment. Second, iron is potentially toxic by participating in the generation of toxic 
oxygen radicals. Consequently, while iron is accumulated in amounts sufficient for metabolism, 
organisms must ensure that their intracellular concentration of "free" iron does not reach toxic 
levels.  
 
To avoid iron excess and its potential toxic consequences while at the same time providing 
enough of iron for growth and development, iron homeostasis must be tightly controlled at 
both the cellular and systemic levels. Iron needs to be transported and safely stored, processes 
that are mediated by a number of specialized proteins involved in maintaining iron 
homeostasis such as to ensure the acquisition of iron and its distribution to different organs 
and tissues, as well as intracellular organelles. 
 
2.1 Cellular iron homeostasis 
At the cellular level, iron homeostasis is achieved through the coordinated regulation of iron 
uptake, storage, export and management of intracellular iron distribution. Importantly, cellular 
iron homeostasis seems to be differentially regulated in iron-acceptor cells (primarily erythroid 
precursors) and in iron-donor cells (macrophages, hepatocytes and intestinal epithelial cells in 
the duodenum). Figure 3 summarizes the general mechanisms that intervene in the uptake, 
intracellular distribution and transport of iron to cell populations. 
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 2.1.1 Cellular iron uptake  
Under normal physiological conditions, virtually all iron in circulation is bound to transferrin 
(Tf), an abundant plasma glycoprotein that can bind one or two ferric ions with high affinity 
[28]. Therefore, nearly all-cellular acquisition of iron from blood occurs via transferrin receptor 
1 and 2 (TfR1- and TfR2-) mediated uptake. 
 
TfR-mediated iron uptake 
In circulation, iron-free Tf, or apoTf, captures extracellular ferric iron and forms the 
diferric-Tf (holoTf) complex that has high affinity for TfR1 expressed at the cell surface. The 
Tf/TfR1 complex is then internalized via endocytosis into endosomes. Acidification of the 
early endosomes through the entry of protons (pH=5.5) triggers conformational changes in 
both Tf and TfR1, facilitating the release of ferric iron from the Tf/TfR1 complex. 
Subsequently, the STEAP3 ferrireductase (six-transmembrane epithelial antigen of prostate 3) 
reduces ferric iron to ferrous iron (Fe
2+
) [29] allowing its transportation across the endosomal 
membrane into the cytoplasm by the divalent metal transporter 1 (DMT1; also known as 
Natural Resistance Associated Macrophage Protein 2, or NRAMP2) [30]. The apoTf/TfR1 
complex is then recycled back to the cell surface and apoTf is released into the bloodstream to 
recapture ferric iron, thereby completing the transferrin cycle (Figure 3).  
 
The TfR1 is ubiquitously expressed at lower levels in normal cells and at higher levels on 
proliferating cells and cells that require high amounts of iron, such as intestinal epithelial cells 
[31], placental trophoblasts and erythroid precursors [32]. A homologue of TfR1, termed TfR2, 
has additionally been identified [33]. Unlike TfR1, TfR2 is exclusively expressed in liver 
hepatocytes, duodenal crypt cells and early erythroid precursors [34] [35]. Similar to TfR1, 
TfR2 binds to Tf at the cell surface and mediates iron uptake by binding to Tf. However, TfR2 
has a 25-fold lower affinity for Tf compared to TfR1 [33, 36] and seems to be pivotal for iron 
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uptake during embryonic development, particularly from day 13 to postnatal day 1, a period 
during which TfR1 expression is suppressed while TfR2 is activated in hepatocytes [35].  
 
Non-transferrin bound iron (NTBI) uptake 
Besides Tf iron, which represents the normal form of circulating iron, a second mechanism of 
iron uptake occurs through a transferrin-independent process. This NTBI transport process is 
considered to have a minor role in iron uptake under normal physiological conditions but 
becomes the primary uptake mechanism when serum iron is severely elevated and surpasses 
the iron-biding capacity of Tf, as seen in primary and secondary iron overload disorders [37]. 
NTBI has been directly connected with the production of harmful ROS and ensuing tissue 
damage, as most organs, including the liver, heart, pancreas and brain have a high capacity to 
rapidly uptake NTBI. The mechanism(s) responsible for NTBI uptake remain to be fully 
understood, however several molecules, including DMT1, ZIP14 (also known as Slc39a14), 
and L-type voltage-dependent calcium channels (L-type VDCC) have all been implicated in 
NTBI uptake.  
 
DMT1. Divalent metals such as Mn and Zn are able to inhibit NTBI uptake by mouse 
hepatocytes indicating that NTBI may share the same transporter with other divalent metals. 
DMT1 has been proposed to be a putative transporter of NTBI in hepatic cells under iron 
overloading situations, because DMT1 expression is upregulated in the liver of 
iron-overloaded mice [38]. However, DMT1-deficient mice are able to develop hepatic iron 
overload, suggesting that another alternative pathway could play a major role in Fe
3+
 uptake 
and indicating that there is an alternative iron-transporter for hepatic NTBI uptake [39, 40]. 
 
ZIP14. The Zrt/Irt-like protein 14 is a zinc transporter that is also involved in NTBI uptake by 
hepatocytes [41]. When ZIP14 is overexpressed in the AML12 mouse hepatocyte cell line, 
NTBI uptake increases, while the opposite occurs when the expression of the endogenous 
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ZIP14 is suppressed [41].  
 
LVDCC. The L-type voltage-dependent calcium channels, where “L" stands for long-lasting 
activation, represent a group of calcium channels that allow the influx of Ca
2+
 essential for 
normal excitability and excitation-contraction coupling in cardiomyocytes. Several findings 
have been shown to support the role of LVDCC in cardiac NTBI uptake [42]. For example, 
LVDCC agonists can augment myocyte iron uptake by perfused rat hearts, while conversely, 
LVDCC blockers have an inhibitory effect [43]. Moreover, treatment of iron-loaded mice with 
LVDCC blockers, such as amlodipine and verapamil, were shown to inhibit LVDCC current in 
cardiomyocytes, reduce myocardial iron accumulation and improve survival [44]. Conversely, 
overexpression of LVDCC in transgenic mice was shown to lead to increased myocardial iron 
accumulation and oxidative stress, resulting in impaired cardiac function in comparison with 
wild-type mice [44]. More recently, it has been demonstrated that, unlike wild-type mice, 
treatments of DMT1-deficient mice with the LVDCC blocker nifedipine had no effect in 
reducing iron accumulation in the liver, suggesting that this effect of nifedipine-mediated 
modulation of iron transport occurs trough DMT1 [45]. However, McKenzie et al reported that 
photodegraded nifedipine is an iron-specific ionophore, and the ionophore effect was 
independent of DMT1[46]. Despite these discrepancies regarding the mechanism of action, 
these findings suggest that nifedipine could possibly be beneficial in iron overload 
cardiomyopathy.  
 
Alternative iron uptake systems 
Some specific cell types have additional means to take up iron, usually involving 
receptor-mediated endocytosis of other forms of protein-bound iron. For example, survival of 
kidney cells in culture has been shown to be regulated by lipocalin 2-dependent endocytosis of 
an iron-laden siderophore via the SLC22A17 lipocalin receptor [47]. In addition, some cells can 
uptake serum ferritin through the Scara5 (scavenger receptor class A, member 5) and TIM-2 (T 
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cell immunoglobulin and mucin domain containing 2) ferritin receptors [48, 49].Another 
source of iron for some specialized cells is represented by heme. For example, SLC48A1 has 
been identified as a heme import molecule [50]. Macrophages can uptake heme indirectly, 
through phagocytosis of senescent and dying red blood cells (RBC). Finally, in plasma, 
hemoglobin and free heme arising from intravascular hemolysis are cleared by specific 
scavenger systems: hemoglobin forms a complex with haptoglobin that is delivered to 
macrophages via CD163-mediated endocytosis [51, 52], while free heme binds to hemopexin 
and the complex is endocytosed via the CD91 receptor present on the surface of macrophages, 
hepatocytes, and other cell types [53]. 
 
2.1.2 Cellular iron storage  
Once uptaken into the cell, iron that is not immediately utilized or exported is stored within 
ferritin, the major iron-storage protein in the body. Ferritin is a conserved protein that 
assembles into a large shell-like structure. Its structure possesses a cavity that provides space 
to accommodate up to 4500 iron atoms. Thus, ferritin can sequester excess intracellular iron in 
a redox inactive form to achieve the purpose of storage and detoxification. Ferritin is 
composed of a combination of 24 subunits of heavy (FtH) and light (FtL) chains with the 
expression ratio of FtH/FtL chains varies depending on the tissue. For example, FtH is highly 
expressed in the heart, while FtL expression is increased in the liver. The FtH/FtL ratio also 
changes in response to inflammation and infection. Functionally, FtH has a potent ferroxidase 
activity that catalyzes the oxidation of ferrous iron, essential for iron internalization and 
packing into the mineral core. In turn, the FtL subunit is involved in iron nucleation and 
protein stability. Iron stored in ferritin is thought to be bioavailable and is mobilized for 
cellular utilization mainly during lysosomal and proteasomal turnover [54]. Serum ferritin is 
mostly composed of the FtL isoform and as such, contains negligible iron levels but is useful 
as a marker for body iron storage levels if no inflammatory or infectious conditions are present 
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[55]. In addition to this major form of ferritin, mitochondria also contain a nuclear-encoded 
H-type ferritin homopolymer, designated mitochondrial ferritin (FtMt) [56]. FtMt is mostly 
detected in mitochondrial-rich tissues, including heart, pancreas and kidney. Under normal 
conditions, FtMt is not involved in mitochondrial iron utilization. However, the expression of 
FtMt in patients suffering from sideroblastic anaemia rises significantly in iron-loaded ring 
erythroblasts (sideroblasts), indicating that FtMt may play an important role in the 
detoxification of iron within this organelle [57].  
 
2.1.3 Iron usage in the mitochondria 
Mitochondria perform an important role in the control of cellular iron metabolism. They 
constitute the major subcellular site of iron utilization, as the sole site for heme 
biosynthesis[58], as well as the major site for Fe–S cluster protein assembly [59]. The exact 
mechanism(s) by which mitochondria acquire iron is not fully understood. The inner 
mitochondrial membrane contains iron transporters that traffic iron from the cytosol into the 
mitochondrial matrix. Mitoferrin has been recently identified as a mitochondrial iron importer 
important for iron uptake in both erythroid and non-erythroid cells [60, 61], as exemplified by 
the fact that mutating mouse mitoferrin leads to impaired heme synthesis due to defective 
mitochondrial iron uptake [60]. In addition to mitoferrin, an endogenous mammalian 
siderophore, namely 2,5-dihydroxybenzoic acid (2,5-DHBA), has been proposed to be 
involved in mitochondrial iron uptake. In this case, iron is imported into the mitochondria in 
the form of an iron-siderophore complex [62]. Several studies suggest that in erythroid cells, 
iron-loaded endosomes directly deliver iron to mitochondria through a transient and rapid 
contact, in a process that has been termed “kiss-and-run” [63]. 
 
Once iron enters the mitochondria, it can be used for heme biosynthesis, Fe–S cluster protein 
assembly or it is stored in mitochondrial ferritin. For heme synthesis, iron is exported toward 
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the cytosol and further inserted into hemoproteins, such as hemoglobin or in cytochromes. In 
response to iron deficiency, mammalian cells enhance mitochondrial iron uptake to maintain 
vital mitochondrial functions that are Fe-dependent [64], and suppress multiple Fe-dependent 
pathways, such as Fe-S cluster scaffold proteins, Nfu1 and Isa1, to limit the utilization of 
cellular iron [65]. A matrix protein called frataxin [66] has been identified as a possible 
regulator of mitochondrial iron export [67] and storage [68]. In humans, inappropriate 
expression of frataxin due an intronic GAA triplet repeat expansion causes the 
neurodegenerative disorder Friedreich ataxia [69], an autosomal recessive disease in which 
accumulation of iron within the mitochondria has been reported both in humans [70] and animal 
models [71, 72].  
 
2.1.4 Cellular iron export 
Ferroportin (FPN, also known as Ireg1 and MTP1) is the only known mammalian iron 
exporter identified so far [73-75]. While FPN is ubiquitously expressed, higher levels are 
found in cells that are crucial for cellular iron homeostasis, such as duodenal enterocytes, 
macrophages, hepatocytes and, interestingly, also in cells of the central nervous system. 
Intestinal enterocytes are responsible for iron transfer into the body, while macrophages are 
the major sites for iron recycling. FPN-mediated iron export depends on the activity of the 
copper-dependent ferroxidase hephaestin in enterocytes, while all other cells require 
ceruloplasmin, another copper-dependent ferroxidase present in the plasma, to successfully 
export iron. Cherukuri et al proposed ceruloplasmin could share responsibility with hephaestin 
for iron absorption under stress in the intestine [76]. These ferrioxidases convert Fe
2+
 to Fe
3+
, 
the iron form that can then bind plasma transferrin. Mice with hephaestin deficiency develop 
anemia due to defective iron-export from enterocytes into the body to complete the process of 
intestinal iron absorption [77]. In humans, mutations in the ceruloplasmin gene result in iron 
accumulation in macrophages, hepatocytes, and cells of the central nervous system, causing 
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iron-restricted anemia and neurodegeneration, as seen in aceruloplasminemia, an autosomal 
recessive disorder [78, 79].  
 
FPN-mediated iron-export is highly regulated and this regulation is essential for iron 
acquisition, utilization and storage. At the transcriptional level, FPN mRNA levels are 
augmented in response to increased erythropoiesis [80], iron, heme and other transition metals 
[81-84], and conversely, mRNA levels are inhibited during inflammation [85]. At the 
translational level, expression of FPN is controlled by the iron regulatory proteins (IRPs) 1 and 
2. FPN can additionally be regulated at the post-translational level by a small antimicrobial 
peptide called hepcidin [86]. Last but not least, in addition to FPN-mediated iron export, cells 
may also export iron in the form of heme and ferritin, as previously mentioned. 
2.1.5 Regulation of cellular iron homeostasis 
To achieve cellular iron homeostasis, iron uptake, storage, utilization, and export must be 
coordinately regulated. The post-transcriptional regulation of these processes by IRPs through 
their interaction with iron-responsive elements (IREs), the so-called IRE/IRP system, is very 
well characterized. IRPs belong to the iron-sulfur cluster (ISC) isomerase family and include 
two IRP homologue proteins, IRP1 and IRP2. IRPs bind to evolutionarily-conserved 
cis-regulatory hairpin structures called IREs, which are located at the 5′ or 3′ mRNA 
untranslated regions (UTRs) [52]. Cellular iron levels regulate the interaction between IREs 
and IRPs through different mechanisms. More specifically, IRP1 is regulated in a reversible 
manner through Fe/S assembly/disassembly, while IRP2 is regulated in an irreversible manner, 
at the level of protein stability. In the presence of high intracellular iron levels, IRP1 binds to a 
[4Fe-4S] cluster, namely cytoplasmic aconitase, leaving the IREs free. When cellular iron 
levels are low, IRP1 binds to IREs [87]. The conversion between holo-IRP1 and apo-IRP1 
mainly depends on mitochondrial iron availability and Fe/S cluster production. Although IRP2 
does not contain a Fe/S cluster, several signals including activity of a 
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2-oxoglutarate-dependent oxygenase(s) may be involved in IRP2 degradation in response to 
iron[88]. Non-iron signals are also involved in IRE/IRP binding regulation. For example, nitric 
oxide (NO) favors apo-IRP1 formation and inhibits IRP2 degradation while hypoxia 
conditions induce holo-IRP1 formation and stabilize IRP2.  
 
How intracellular iron regulates iron uptake and storage via the IRE/IRP system is best 
exemplified by the regulation of TfR1 and ferritin [52]. For TfR1, IREs are located at the 3′ 
UTR mRNAs, while ferritin IRE is located at the 5′ UTR of the mRNAs encoding FtH and FtL 
chains. In iron-deficient cells, IRE/IRP interaction with the 3′ UTR stabilizes TfR1 mRNA 
[89]. However, 5′ UTR binding of IRPs to their IREs inhibits the early steps of the translation 
process [90]. As a result, TfR1 expression levels are increased and de novo ferritin synthesis is 
suppressed, leading to increased cellular iron uptake via TfR1 and decreased iron storage to 
counteract iron deficiency. In iron-abundant cells, the binding of IREs to IRPs is inhibited, 
resulting in TfR1 mRNA degradation and ferritin mRNA translation. This will limit iron 
uptake via TfR1 preventing iron excess while augmenting ferritin synthesis to safely store iron 
within the cell.  
 
Besides their presence in TfR1 and ferritin, IREs have been identified also at the 5′ UTR of 
mRNAs encoding ALAS2 (iron utilization), an enzyme that catalyzes the first step of heme 
synthesis in the mitochondria of erythroblasts. Both IRPs when bound to ALAS2 IRE can 
inhibit ALAS2 mRNA translation [91]. IREs are also present at the 5′ UTR of mRNAs 
encoding ferroportin (export) [73], mitochondrial aconitase (a citrate cycle enzyme) [92] and 
hypoxia-inducible factor- (HIF-) 2α [93], and at the 3′ UTR of mRNAs encoding DMT1 
(uptake) [94]. In contrast to TfR1, the mRNAs encoding TfR2 and mitochondrial ferritin do 
not possess IREs, and as such are not regulated through the IRE/IRP system. 
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Figure 3 Depicition of iron import (top) and export (bottom) pathways in a generic 
mammalian cell.  
Iron uptake, storage and export mechanisms and some regulatory elements are shown. TfR1 - 
transferrin receptor-1; TfR2 - transferrin receptor-2; DMT1 – divalent metal transporter 1; 
Dcytb - duodenal cytochrome b-like ferrireductase; CD163 - hemoglobin scavenger receptor; 
IRP-1 - iron regulatory protein-1. Steap-3 - six-transmembrane epithelial antigen of prostate 3. 
Modified from [95]. 
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2.2 Systemic iron homeostasis 
Because mammals have no regulated mechanism for the elimination of excess iron, the control 
of iron balance requires a fine adjustment in iron absorption by intestinal enterocytes and the 
recycling of iron by macrophages. Regulatory effectors that modulate intestinal iron 
absorption probably also regulate the release of iron from tissue macrophages and hepatocytes. 
 
The levels of intestinal iron absorption are regulated by both systemic and local enterocyte 
iron status. Changes in enterocyte iron concentrations serve as a fine-tuning mechanism of 
intestinal iron absorption through the “mucosal block” that occurs several hours after 
consumption of a large dose of iron [96]. The decrease in intestinal iron absorption occurring 
following an oral dose of iron is associated with increased enterocyte iron levels, as assessed 
by IRP activity and ferritin immunoblotting. Reduced iron absorption is also accompanied by 
a rapid decrease in expression of the mRNAs encoding the brush border iron transport 
molecules Dcytb and DMT1 containing the IRE splice variant[97]. Thus, in the brush border, 
but not in the basolateral border, iron transport components are regulated locally by enterocyte 
iron levels, which support the hypothesis that systemic stimuli exert their primary effect on 
basolateral transport molecules. 
More recently, Bruno Galy et al[98] found that IRPs inhibit the expression of both FPN and 
DMT1 in adult mice. However, intestine-specific IRP-deficient mice fail to absorb adequate 
amounts of iron in spite of the high expression levels of the iron transporters DMT1 and FPN. 
IRP ablation also results in iron retention in enterocytes. For over a half century, people have 
believed enterocytic ferritin can limit dietary iron intake [99, 100]. Thus, the mucosal block in 
IRP-deficient mice likely results from iron withholding by the large excess of mucosal ferritin. 
Bruno Galy et al further showed ferritin actually only traps a minor fraction of the iron 
transiting through enterocytes. Their results suggest a dual function of IRPs in the regulation 
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of iron absorption: IRPs limit apical and basolateral iron transport and also ensure sufficient 
passage of iron through the enterocyte by counteracting the diversion of the metal into ferritin. 
 
Besides the IRP/IRE interaction, some iron sensing proteins are additionally involved in the 
regulation of iron absorption. HIF2α is shown to be involved in directly regulating the 
transcription of the gene encoding DMT1, the major intestinal iron transporter [101] and FPN, 
the only known iron exporter [98, 102]. Intestinal specific deletion of HIF2α results in the 
decrease of hepatic and serum iron levels [101]. HIF2α levels are dependent on prolyl 
hydroxylase domain (PHD) enzymes that require ferrous iron for their enzymatic activity 
[103]. Therefore, PHD enzymes serve as iron sensing proteins that regulate iron absorption.  
 
Intestinal iron absorption is modulated by 4 major regulators: body iron stores, erythropoiesis, 
hypoxia and inflammation [104]. The regulation of these factors results in the variation of 
hepcidin levels, a small antimicrobial peptide secreted by hepatocytes [105, 106] which 
functions as an inhibitor of iron absorption [107]. The discovery of hepcidin and its central 
role in iron metabolism have clarified the pathological mechanisms of most common iron 
disorders. Mice deficient in hepcidin develop iron overload [108], while mice overexpressing 
it present profound iron deficiency [109]. A change in hepcidin levels subsequently targets the 
expression of the iron-exporter FPN [107] in duodenal absorptive cells and macrophages, and 
consequently the amount of iron entering the body and being recycled by macrophages.  
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3. Hepcidin 
The discovery of the iron regulatory hormone hepcidin has provided a consistent model of iron 
homeostasis that allows for a better understanding of the importance of sensors at the cellular 
level for iron needs, as well as of the pathophysiology of hereditary iron metabolism disorders 
such as hemochromatosis and anemia of inflammation (or anemia of chronic disorders) [110].  
 
3.1 The discovery of hepcidin 
 
Hepcidin, also named LEAP-1, was initially identified as an antimicrobial peptide in human 
urine and serum by two independent groups [105, 111]. The link between hepcidin and iron 
metabolism was first discovered by Sophie Vaulont’s group [108]. The group determined that 
USF2 (upstream stimulatory factor 2) knockout mice unexpectedly experienced severe iron 
overload with iron deposition in the liver and pancreas. The iron dysregulation observed in 
USF knockout mice was found to be related to the accidental knockout of a neighbor gene, 
identified as hepcidin, in the construct used for generating the USF2 knockout mice [108]. 
Further evidence of hepcidin involvement in iron metabolism was then demonstrated with the 
generation of transgenic mice overexpressing hepcidin under the control of a liver-specific 
promoter, leading to the development of severe iron deficiency anemia and premature death of 
transgenic mice [109].  
 
Further studies showed that the hepcidin gene is evolutionarily conserved across vertebrate 
species from fish to humans [112]. The human genome contains only one copy of the hepcidin 
gene [112], whereas there are duplicate copies in the mouse (Hepc1 and Hepc2) genome [106, 
 31 
108] and two or more copies in certain fishes [113, 114]. In mice, both Hepc1 and Hepc2 are 
homologous to human hepcidin, but only hepc1 plays a role in iron metabolism [115]. Hepc2 
is not an inactive pseudogene since it is expressed in high levels and subjected to certain 
regulation. It shares some structural similarities with fish hepcidin-like peptides, which 
suggests Hepc2 serves a similar function as these fish hepcidin-like peptides, that is, 
antimicrobial activity [115].  
 
The human hepcidin gene (HAMP) maps to chromosome 19q13.1. It comprises two introns 
and three exons encoding a precursor protein of 84 aa, called preprohepcidin. Preprohepcidin 
undergoes enzymatic cleavage during its export from the cytoplasm resulting in a 64 aa 
prohepcidin that is released into the endoplasmic reticulum [116]. Next, a 39 aa pro-region 
peptide is post-translationally removed by a furin-like proprotein convertase which results in 
the production of mature bioactive hepcidin-25 (25-aa form), identified both in blood and 
urine [105, 111]. In urine, two N-terminally truncated isoforms of 22-aa and 20-aa have also 
been detected. These two isoforms do not seem to have any identified iron-regulatory activity, 
suggesting that they are degradation products of the hepcidin-25 form [105].  
 
Further studies using nuclear magnetic resonance spectroscopy (NMR) showed that 
hepcidin-25 it’s a simple hairpin-shaped, cysteine-rich peptide with distorted -sheets linked 
by four disulfide bridges. Three disulfide bridges stabilize the two anti-parallel strands while 
the fourth bridge is located in the vicinity of the hairpin loop which is more stressed and could 
have greater chemical reactivity [117] (Figure 4). Structure function analysis indicated that the 
iron regulatory activity requires the full-length peptide (hepcidin-25). The 20-aa, N-terminally 
truncated hepcidin has no iron-regulating bioactivity, indicating that the five N-terminal amino 
acids are crucial for this activity [118, 119].  
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Hepcidin structure closely resembles the cysteine-rich antimicrobial peptide defensins. It has a 
positively charged hydrophilic residue located on the concave side, and a hydrophobic residue 
distributed on the convex side, a typical structure of antimicrobial peptides known to disrupt 
bacterial membranes [120]. Several studies have shown that hepcidin indeed possesses 
antimicrobial properties [105, 116, 121, 122]. However, very high levels of hepcidin are 
required in order to achieve antimicrobial activity, about 100-fold higher than necessary for its 
iron regulatory activity[105]. 
 
Several studies suggest that the hepcidin gene is expressed in multiple tissues. The highest 
expression is predominantly in the liver of mammals and most fishes [105, 111-113, 123-126], 
and weaker expression can also be detected in the heart, lungs, spinal cord, stomach, intestine, 
pancreas, adipocytes, skeletal muscle, and testis [127-133]. Myeloid cells, including 
monocytes, macrophages and neutrophils, also express hepcidin [134-138]. Hepcidin 
expression is regulated differently in macrophages and in hepatocytes. Direct iron-loading 
does not induce hepcidin production in mouse macrophages [134], much as BMP6 treatment 
fails to, but LPS and IL-6 stimulation leads to hepcidin induction in these cells [139]. In 
addition, hepcidin can also be induced in macrophages by gram-positive and gram-negative 
bacteria wall constituents, through toll-like receptor (TLR) 2 and TLR4, which favors iron 
retention in macrophages and promotes host defense [135, 140]. Moreover, TLR-mediated 
hepcidin induction requires signaling through the MyD88-dependent pathway [140].  
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Figure 4 Hepcidin-25 structure  
Front: overview of the structure of hepcidin-25. Distorted β-sheets are shown as grey arrows, 
and the peptide backbone is colored gray. The disulfide bonds are colored yellow, highlighting 
the position of an unusual vicinal bond between adjacent cysteines at the hairpin turn. Positive 
residues of arginine (Arg) and lysine (Lys) are pictured in blue, the negative residue of aspartic 
acid (Asp) in red, and the histidine-containing Cu
2+
- Ni
2+
 (ATCUN)-binding motif in the 
N-terminal region is colored green. Background: hepcidin-25 molecule displayed with 
solvent-accessible surface that illustrates the amphipathic structure of the molecule. The 
molecule is colored gray, except for the side-chains of positive (blue) and negative (red) 
residues. Figure obtained from [141] (permission obtained from Journal Haematologica). 
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3.2 Regulation of hepcidin synthesis 
Considering the close relationship between iron metabolism and hepcidin, the same factors 
that influence dietary iron absorption, namely iron stores, erythropoietic activity, hemoglobin, 
oxygen content and inflammation, are also capable of regulating the expression of hepcidin in 
hepatocytes. Recent advances in understanding how hepcidin is regulated at the molecular 
level have expanded our knowledge about the pathways regulating iron metabolism. 
 
3.2.1 Iron-sensing pathway of hepcidin regulation 
The regulation of hepcidin by body iron levels acts through a negative feedback mechanism. 
In both mice and men, hepcidin expression is induced by iron loading [106, 142] leading to 
inhibition of intestinal iron absorption and iron release from macrophages. Conversely, 
hepcidin expression is suppressed in iron deficiency [143], promoting intestinal iron 
absorption and iron release from macrophages into the circulation. Hepcidin is mainly 
expressed in the liver, and it is therefore most likely that iron-sensing takes place in this organ.  
However, direct iron treatment of both primary hepatocytes and hepatocytes cell lines leads to 
reduced hepcidin expression rather than activation [142], indicating that iron-sensing by 
hepatocytes in vivo involves the collaborative interaction between cell types, such as Kupffer 
cells. Studies in patients with an iron-overload disease, hereditary hemochromatosis (HH) and 
juvenile hemochromatosis (JH), revealed several proteins that are involved in hepcidin 
regulation by iron. HH and JH are a group of genetic disorders caused by mutations in the 
HFE, TfR2, hepcidin, and hemojuvelin (HJV) genes [144-149]. Despite iron accumulation in 
several organs in patients with HH and JH, hepcidin expression is inappropriately defective, 
clearly indicating that all molecules involved (HFE, TfR2, hepcidin and HJV) are crucial for 
hepcidin activation by iron.  
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3.2.2 Inflammatory pathway of hepcidin regulation 
Hepcidin synthesis is also significantly increased during inflammation due to infection, 
autoimmune disease, and cancer. Excess hepcidin production in these settings inhibits dietary 
iron absorption and sequesters iron inside macrophages, resulting in low levels of circulating 
iron in the plasma, or hypoferremia. The finding that hepcidin-deficient mice do not develop 
hypoferremia upon inflammatory stimuli further demonstrates that hepcidin is a crucial player 
in the hypoferremic response accompanying inflammation [150]. Hypoferremia is often 
understood as a host defense response aimed at limiting iron availability to microorganisms. 
However, sustained hypoferremia over significant time may lead to the development of the 
anemia of chronic disease, or functional anemia [151].  
 
Hepcidin induction by inflammatory stimuli is predominantly mediated by interleukin-6 (IL-6) 
[150, 152]. IL-6 administration in mice and humans rapidly (within hours) induces hepcidin 
excretion, and is concomitantly accompanied by a significant decrease in serum iron and 
transferrin saturation [150]. How does hypoferremia develop so rapidly? The plasma 
transferrin compartment contains approximately 2–4 mg of iron, which accounts for 1% of 
total body iron content. This transit compartment flows about 20 mg of iron each day, thus, the 
entire content of iron in plasma turns over every 3–4 hours[9]. Only 1 to 2 mg of iron are 
obtained from intestinal absorption, and most iron is recycled from senescent erythrocytes. If 
hepcidin could completely block iron recycling, in one hour plasma iron would drop by at 
least 25%, consistent with the degree of hypoferremia observed in humans infused with IL-6 
[150]. In vitro studies further demonstrate that primary hepatocytes treated with IL-6 are also 
capable of increasing hepcidin synthesis, an induction that can be efficiently blocked by 
pre-treatment with anti-IL-6 antibodies [150].  
 
IL-6 has been believed to be the only cytokine responsible for hepcidin stimulation in human 
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hepatocytes [152] and Hep3B cells [150]. However, later studies showed that IL-6-deficient 
mice still respond to LPS and produce hepcidin [153]. Therefore, other cytokines must also 
contribute to the regulation of hepcidin in hepatocytes. In murine hepatocytes, IL-1 and 
IL-1 are able to stimulate hepcidin transcription, while IFN- shows an inhibitory effect 
[154]. Similarly, in other cell types, hepcidin is also regulated by cytokines. In human 
monocytes, IL-6 and IFN- are capable of inducing hepcidin, while TNF- can inhibit 
hepcidin induction by IL-6 [155]. A recent study found that hepcidin expression is induced by 
both IFN- and IL-6 in human airway epithelial cell lines [156]. The study also demonstrates 
that hepcidin induction by IFN- is independent of IL-6 and that it signals via the JAK/STAT1 
cascade to activate hepcidin. 
 
3.2.3 Regulation of hepcidin in response to erythropoietic demand 
Erythropoiesis is the process by which RBCs are produced, by consuming most of the iron 
absorbed from the diet or recycled from hemoglobin by macrophages. Increased erythropoietic 
activity suppresses hepcidin expression promoting dietary iron absorption and mobilizing iron 
release from storage sites, resulting in more iron being available for erythropoiesis. Both 
hypoxia and anemia stimulate erythropoiesis through the production of erythropoietin (EPO). 
Accordingly, EPO administration in humans and mice suppresses hepcidin expression [157, 
158]. Recent studies have shed some light on whether EPO acts directly or indirectly to 
suppress hepcidin expression. In mice that received full-body irradiation to block 
erythropoiesis, EPO-mediated suppression of hepcidin is prevented [159]. Similarly, when 
mice that were rendered anemic by bleeding or chemical hemolysis are pretreated with 
erythropoiesis inhibitors, such as carboplatin or doxorubicin, EPO-mediated hepcidin 
suppression is also abolished [159, 160]. These studies indicate that EPO acts indirectly, 
possibly through soluble mediators, to mediate hepcidin suppression and it requires 
erythropoiesis activity. More recent studies suggest that growth differentiation factor 15 
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(GDF15), and twisted gastrulation protein (TWSG1) both of which are released by erythroid 
precursors during accelerated erythropoiesis, are the most likely candidates mediating hepcidin 
suppression in response to erythropoietic demand [161, 162]. GDF15, a member of the 
transforming growth factor-β superfamily, was found at high levels in the serum of patients 
suffering from -thalassemia and congenital dyserythropoietic anemia (CDA) [161, 163, 164]. 
Furthermore, human hepatocytes treated with serum from -thalassemia patients showed a 
decreased hepcidin expression, which could be reversed by depletion of GDF15 [161]. Thus, 
GDF15 acts as an erythroid factor by down-regulating hepcidin expression in these patients. 
However, immunoprecipitation of GDF15 in the sera of -thalassemia patients did not 
completely abolish hepcidin suppression in exposed hepatocytes, suggesting that GDF15 is 
likely not the sole mediator of hepcidin suppression. In fact, further studies identified yet 
another mediator, TWSG1, found to be elevated in a murine model of -thalassemia major 
[162]. TWSG1 is a BMP-binding protein that can suppress hepcidin expression in human 
hepatocytes through a BMP-dependent mechanism. Further studies showed that this regulation 
involved the inhibition of BMP-dependent activation of the SMAD-mediated signal 
transduction pathway [162].  
 
Both in vivo and in vitro studies have additionally showed that hepcidin expression is also 
suppressed by hypoxia [143, 158]. Hypoxia per se induces EPO production in the kidney and 
liver, and as such would contribute to increase erythropoiesis and consequently suppress 
hepcidin production. Hypoxia-inducible transcription factors (HIFs) are the central mediators 
of hypoxia-induced erythropoiesis. HIFs consist of an O2 and iron-sensitive α subunit (HIF-1α 
and HIF-2α,) and a constitutively expressed β subunit, HIF-β. Under normoxic conditions, 
HIF is subjected to degradation by the von-Hippel–Lindau (VHL) ubiquitin ligase, a tumor 
suppressor protein via an iron-dependent mechanism[165]. Under hypoxic conditions, HIFs 
are stabilized and function as transcriptional factors to adapt to oxygen change [166]. Hepatic 
deletion of HIF1α in mice leads to increased hepcidin expression even when mice are rendered 
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iron-deficient through an iron-depleted diet. Furthermore, mice with liver-specific deletion the 
VHL gene express extremely low levels of hepcidin [167]. Thus, the VHL/HIF axis is 
essential for oxygen sensing and hepcidin regulation. The study of Mastrogiannaki M et al. 
indicated that hepcidin suppression by hepatic HIF-2 required enhanced erythropoietic activity 
[168]. Similarly, Liu Q et al found that Hamp1 suppression requires Epo-induced 
erythropoiesis [169]. The human hepcidin promoter contains several consensus-binding sites 
for HIF suggesting that hypoxia may also directly regulate hepcidin via HIF at the 
transcriptional level [167]. In addition, ROS are also involved in the hypoxic regulation of 
hepcidin.  Last but not least, HepG2 cells incubated in hypoxic conditions markedly 
increased ROS levels and decreased hepcidin expression, and anti-oxidant treatments can 
reverse this inhibition. Further studies examined the role played by several transcriptional 
factors and found that C/EBPα and STAT3 dissociate from hepcidin under hypoxic conditions, 
an effect that also can be reversed by anti-oxidant treatment. Thus, ROS may suppress 
hepcidin expression via preventing C/EBPα and STAT3 binding to the hepcidin promoter 
during hypoxia [170] . 
 
3.3 The hepcidin/ferroportin axis  
Substantial progress has been made recently in elucidating the mechanism of action of 
hepcidin. Hepcidin acts by inhibiting the expression of the FPN protein both in enterocytes and 
macrophages [171, 172]. 
 
The concentration of FPN on the cell surface is controlled by both the rate of FPN synthesis 
and degradation among other factors. In vitro studies demonstrated that hepcidin mediates 
FPN internalization and degradation [86]. Hepcidin-mediated FPN internalization requires the 
activity of two of FPN lysines that may be targets of ubiquitination [173]. Internalized FPN is 
subjected to mono-ubiquitination and is targeted for degradation [86, 172]. The hepcidin-FPN 
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interaction forms an iron homeostasis loop: iron induces hepcidin production, which then 
regulates FPN concentration at the cell surface. When iron levels are high, hepcidin is 
produced and targets FPN for degradation on the basolateral membrane of absorptive 
enterocytes, thereby blocking the transfer of iron from enterocytes into the plasma. Within two 
days, short-lived absorptive enterocytes are shed into the intestinal lumen and the iron 
sequestered in these cells is consequently removed from the body [174]. Similarly, in 
macrophages, hepcidin-mediated FPN degradation results in iron sequestration within these 
cells.  
 
Besides post-translational regulation, FPN expression is additionally regulated at the 
transcriptional level by iron and heme [75, 134, 175-177]. Iron, and some other transition 
metals including zinc, copper, manganese, cobalt, and cadmium, can directly induce FPN 
transcription via unknown mechanism(s) [178, 179]. It has been observed that animal products 
such as meat, fish and poultry enhance non-heme iron absorption in humans. A proposed 
mechanism involves the induction of FPN expression by heme at the transcriptional level via 
the transcription factor Bach1 [81]. Finally, and as already mentioned, FPN levels are also 
regulated post-transcriptionally via the IRE/IRP system [180, 181]. 
 
3.4 Molecular signaling pathways regulating hepcidin expression 
Intensive research during the past 10 years has been conducted to identify the signaling 
pathways involved in hepcidin transcriptional regulation. At the present, two major signaling 
pathways have been identified: the BMP/SMAD iron-sensing pathway and the IL-6/STAT3 
inflammatory pathway, depicted in Figure 7. 
3.4.1 BMP/SMAD4 signaling pathway 
BMPs are a group of secreted molecules that belong to the transforming growth factor-β 
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superfamily. The SMAD proteins are homologs of both the drosophila protein "mothers 
against decapentaplegic" (MAD) and the Caenorhabditis elegans protein SMA, with its name 
deriving from a combination of the two.  In vivo and in vitro studies demonstrated that 
several BMPs, such as BMP2, 4, 6, and 9 can activate HAMP transcription [182, 183]. Further 
studies in liver-specific Smad4-knockout mice revealed that lack of Smad4 in hepatocytes 
results in a 100-fold lower hepcidin transcriptional expression than wild-type mice 
accompanied by massive hepatic iron overload [184]. Furthermore, knockdown of Smad4 in 
mouse primary hepatocytes also ablated the hepcidin induction by BMP4 [184]. These results 
establish that the BMP/SMAD4 pathway is important for hepcidin regulation through the 
iron-sensing pathway. The BMP/SMAD4 iron-sensing pathway can be described as follows: 
iron induces BMP6 expression, which then binds to cell-surface BMP receptor (BMPR) 
complexes that include type I and II (BMPRI and BMPRII) serine/threonine kinase receptors. 
Upon ligand binding, BMPRII phosphorylates BMPRI, leading to further phosphorylation of 
SMAD1/5/8 in the cytosol. Phosphorylated SMDS1/5/8 then form a complex with the 
common mediator SMAD4, translocate into the nucleus and bind to BMP-responsive elements 
(BMPRE) located in the hepcidin promoter and activate hepcidin transcription.  
 
Several elements participating in the iron-sensing pathway mediated by SMAD4 signaling 
have been identified, including BMP6, HJV, TfR2, HFE and TMPRSS6. 
BMP6: BMP6 has emerged to be the essential molecule sensing iron for the BMP/SMAD4 
pathway. In vitro studies showed that BMP2, 4, 6, and 9 can all induce hepcidin production 
[183, 185], however only BMP6 transcription is actually regulated by dietary iron in vivo 
[186]. Accordingly, mice with targeted disruption of BMP6 have reduced phosphorylated 
Smad1/5/8 levels, develop massive iron overload and show undetectable levels of hepcidin 
mRNA in the liver [187, 188]. Finally, administration of exogenous BMP6 directly into mice 
has been shown to induce hepcidin [187]. Collectively, these studies demonstrate that BMP6 is 
essential for hepcidin induction and is a key player in iron sensing. 
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HJV: HJV is a GPI-linked cell-surface protein also known as repulsive guidance molecule C 
(RGMC). HJV interacts with BMP6, BMP4, and BMP2 and functions as a BMP co-receptor 
[189]. Thus, HJV regulates hepcidin expression by enhancing BMP/SMAD4 signaling [190]. 
Mutations in the HJV gene cause juvenile hemochromatosis (JH) in humans and mice, 
characterized by severe iron overload in the liver, pancreas and heart [149, 191]. There are two 
forms of HJV with opposing effects: a membrane-bound form (m-HJV) that can induce 
hepcidin expression and a soluble form (s-HJV) that suppresses hepcidin expression. s-HJV is 
the product of cleavage at the C-terminus of m-HJV by a proprotein convertase, furin [192]. 
Neogenin, a receptor membrane protein, is then required for the release of the s-HJV [193]. 
Neogenin binds to HJV and this interaction is crucial for BMP-dependent signaling of 
hepcidin expression [194]. In addition, s-HJV can also bind to BMPs, thereby preventing the 
interaction between m-HJV and BMPs [190] and functioning as a competitive antagonist of 
m-HJV. Importantly, s-HJV is increased during iron deficiency and hypoxia, possibly due to 
furin activation in these conditions [195]. Conversely, increased iron concentrations reduced 
s-HJV expression in cells overexpressing HJV[195].  
 
TfR2: TfR2 is a homolog of TfR1 mainly expressed in hepatocytes [33]. Similarly to TfR1, 
TfR2 also binds to iron-loaded transferrin, but with much weaker affinity [33, 34]. 
Homozygous mutations in the TfR2 gene cause type 3 HH in humans. Accordingly, mouse 
models with mutated or knockdown of TfR2 present a phenotype similar to human HH, 
associated with reduced hepcidin expression [146, 196]. Unlike TfR1, TfR2 transcription is up 
regulated by increased serum iron possibly due to the stabilization of the TfR2 protein upon 
binding to diferric transferrin [197]. TfR2-mediated hepcidin regulation occurs through its 
interaction with HFE [198].  
 
HFE: Mutations in the HFE gene, encoding a 2-microglobulin-dependent MHC class I-like 
molecule, are associated with type I HH [199, 200]. HFE competes with transferrin for 
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binding to TfR1 and consequently inhibits cellular iron uptake [201, 202]. In addition, HFE is 
also able to bind to TfR2. The presence of iron-loaded transferrin displaces HFE from TFR1, 
and allows HFE to rather bind to TfR2 and form the HFE/TfR2 complex. The HFE/TfR2 
complex subsequently induces SMAD1/5/8 phosphorylation expression via the Erk 
(extracellular signal-regulated kinase) activation pathway, and hence induces hepcidin 
expression [203]. Thus, it has been proposed that BMP6, BMPR, HFE, TfR2 and HJV form a 
super complex at the hepatocyte surface that senses body iron levels [204] and activates 
hepcidin expression through a SMAD4-dependent pathway.  
 
TMPRSS6: TMPRSS6 (transmembrane protease, serine 6), also called matriptase-2, is a 
transmembrane serine protease mainly expressed in the liver [205] that is required for sensing 
iron deficiency. Once activated during iron deficiency, it cleaves m-HJV into small fragments 
[206], resulting in the suppression of BMP signaling and hence hepcidin expression. 
Alternatively, TMPRSS6 is involved in an yet to be identified transmembrane signaling 
pathway activated by iron deficiency, which would then bind to inhibitory elements located in 
the HAMP promoter region [207]. The mechanisms through which TMPRSS6 senses iron 
deficiency are not fully elucidated, however mutations in this gene lead to iron-refractory iron 
deficiency anemia (IRIDA) in humans and mice [207-209]. 
 
3.4.2 IL-6/STAT3 signaling pathway 
As mentioned previously, IL-6 is a crucial cytokine that induces hepcidin during inflammation. 
Further studies have demonstrated that this induction is mediated by STAT3 [210-212]. One 
study showed that IL-6 directly induces hepcidin and activates STAT3 in mouse hepatocytes, 
as assessed by measuring phospho-STAT3 expression. Furthermore, in mice with disrupted 
gp130, the signal transducing unit in the IL-6/IL-6 receptor (gp80), both hepcidin induction 
and STAT3 phosphorylation are blunted. This blunted response suggests that STAT3 is the 
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key transcription factor responsible for IL-6-mediated activation of hepcidin gene expression 
in the liver [212]. Additional studies identified a STAT3 binding motif located at position 
–64/–72 on the hepcidin promoter, which is required for IL-6-mediated hepcidin activation 
and even for basal hepcidin mRNA expression [210, 211]. These studies identified STAT3 as 
necessary and sufficient for IL-6 responsiveness of the hepcidin promoter. So far, the 
IL-6/STAT3 signaling pathway has been described as follows: upon stimulation with 
inflammatory molecules such as LPS [150] and other TLR ligands [213], IL-6 is induced in 
macrophages. IL-6 then binds to its membrane-bound receptor (gp80) on hepatocytes and 
interacts with gp130. Subsequently, the formation of gp130-containing complexes activates 
Janus kinases (JAKs), which in turn, phosphorylate tyrosine residues in the cytoplasmic 
domain of gp130. These phosphotyrosines serve as docking sites for STAT3. Recruited 
STAT3 then becomes phosphorylated on a single tyrosine residue (Y705) and phosphorylated 
STAT3 forms a dimer that translocates into the nucleus, binds to the STAT-responsive element 
on the hepcidin promoter and activates hepcidin transcription [210-212]. 
 
3.4.3 Crosstalk between signaling pathways 
The BMP/SMAD and IL-6/STAT3 signaling pathways are synergistic through a mechanism(s) 
that remains to be elucidated. Several studies suggest that there is a crosstalk between both 
pathways. For example, in vitro studies using Hep3B cells showed that dorsomorphin, a BMP 
receptor inhibitor, could also inhibit hepcidin induction by IL-6 [214]. Even more suggestive 
of such a crosstalk, is the finding that the abolishment of the BMP pathway, as seen in 
liver-specific Smad4
-/-
 mice, leads to blunted responses to IL-6-mediated hepcidin 
transcription [184].  
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Figure 5 Regulatory signaling pathways in hepcidin expression 
In the iron-sensing BMP/SMAD pathway, the binding of BMPs to the BMP receptor induces 
receptor-regulated Smads (Smad1/5/8). Following phosphorylation, Smad1/5/8 heterodimerize 
with Smad4 and co-migrate to the nucleus where it binds to the BMP-response elements 
(BMP-RE) in the hepcidin promoter. Smad1/5/8 can be inhibited by inhibitory Smads (Smad6 
and Smad7), Id1 and Atoh8. The iron sensor complex includes HFE, TfR2 and HJV. HFE is 
regulated by transferrin-bound iron (Holo-Tf). Holo-Tf regulates BMP signaling through 
unknown mechanisms. There are two forms of HJV: membrane-bound and soluble (m-HJV 
and s-HJV). s-HJV is obtained following furin cleavage or proteolytic cleavage by the 
membrane-bound TMPRSS6. 
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4. Interactions between immune system and iron metabolism 
 
Defense against microbes is mediated by the early reactions of innate immunity and the later 
responses of adaptive immunity. Innate immunity, also known as non-specific immunity, is the 
first line of defense, which protects the host from infection by other organisms in a 
non-specific and generic manner. Adaptive immunity, also known as acquired immunity, is 
composed of antibody responses and cell-mediated responses, which eliminate or prevent 
pathogenic growth. It has long been observed that in response to various inflammatory stimuli, 
iron metabolism changes dramatically [215, 216]. Since iron is an essential nutrient for nearly 
all infectious microorganisms as well as for their hosts [217], iron metabolism is targeted as a 
host defense mechanism to prevent the growth of microbial pathogens. Iron metabolism 
changes have been implicated in both innate immunity and adaptive immunity. Once the host 
encounters a pathogen, iron is rapidly sequestered within macrophages and bound to 
specialized extracellular proteins via different mechanisms. This sequestration in turn restricts 
iron availability to certain pathogens at the systemic and cellular levels and thus contributes to 
host defense by delaying pathogen growth [217]. In the next section, several examples of 
proteins involved in iron metabolism having a role in innate immunity are presented.   
 
Lactoferrin 
Lactoferrin is a transferrin family glycoprotein with a high affinity for ferric iron. Synthesized 
by epithelial cells, lactoferrin is found at high levels in mucosal secretions, including tears, 
saliva, bile, nasal secretions and breast milk. It is also present in neutrophil granules and is 
strongly induced at the sites of infection and inflammation [218, 219].  
 
Lactoferrin functions as a potent iron-chelator having the ability to retain iron over a wide 
range of pH. Unlike transferrin, iron bound to lactoferrin cannot be released at the acidic pH 
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[220] prevalent in infected or hypoxic areas. In addition, lactoferrin exhibits a direct effect on 
pathogens, and is thus considered a critical component of innate defense. In fact, both in vivo 
and in vitro studies show that exogenous lactoferrin effectively inhibits bacterial growth [217]. 
The bacteriostatic effect of lactoferrin is due to its ability to sequester iron and as such, deprive 
pathogens of iron absolutely necessary for their growth. Furthermore, lactoferrin has been 
shown to induce the production of proinflammatory cytokines per se, and to promote 
phagocytosis and cell adherence [221, 222]. Despite the strong correlation between exogenous 
lactoferrin and inhibition of bacterial growth, lactoferrin knockout mice do not exhibit major 
abnormalities in the immune system, and do not display enhanced susceptibility to pathogens 
such as Staphylococcus aureus, Pseudomonas aeruginosa and Mycobacterium tuberculosis 
when compared to wild-type animals [217, 223]. These studies suggest that the bacteriostatic 
effect of lactoferrin may be redundant, at least in these mouse models.  
 
Nramp1 
Nramp1 (Natural resistance-associated macrophage protein-1), is a divalent metal-proton 
co-transporter located on the membrane of macrophage and neutrophil phagosomes [224]. 
Nramp1 expression is transcriptionally induced by interferon-γ (IFN-) and lipopolysaccharide 
(LPS) via a mechanism involving interferon regulatory factor 8 (IRF-8) [225]. Nramp1 acts by 
pumping Fe
2+
, Co
2+
 and Mn
2+
 cations out of the phagosomal compartment into the cytosol, 
resulting in the depletion of these nutrients, which could otherwise be exploited by intracelluar 
pathogens. Macrophages represent a choice site for the establishment of intracellular 
phagosomal pathogens such as Salmonella, Mycobacteria, Leishmania and Chlamydia. 
Therefore, an alteration in intra-macrophage iron content and distribution by Nramp1 results in 
the inhibition of the growth of pathogens that live within the phagosome [224, 226]. 
Furthermore, Nramp1-mediated changes in iron distribution may suppress the expression of 
the inhibitory cytokine IL-10 and induce iNOS production by macrophages, thereby restricting 
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microbial growth [227-229]. These mechanisms suggest that functional Nramp1 is required to 
maintain the resistance to intracellular phagosomal pathogen infection.  
 
Lipocalin 2 
Lipocalin 2 has several other names such as siderocalin, neutrophil gelatinase associated 
lipocalin (NGAL) or, in mice, 24p3. Structural studies indicated that lipocalin 2 can bind to 
catecholate-type and salicylate-derived siderophores, such as enterobactin secreted by E. coli 
and mycobactin secreted by M. tuberculosis, respectively [230, 231]. Siderophores are small, 
high affinity iron chelators secreted by microbes to acquire iron from their environment. 
Siderophores can cross the outer membrane of the cell through receptor reorganization [232, 
233]. Lipocalin represents a host defense strategy to prevent siderophore-mediated iron 
utilization by microbes. Lipocalin 2 is secreted by neutrophils, epithelial cells, macrophages 
and other cell types in response to inflammation or infection [228, 234, 235]. It acts as an 
acute-phase protein and sequesters iron to subvert pathogen iron acquisition by certain types of 
siderophores. Lipocalin 2 binds iron as ferric siderophore complexes to limit the growth and 
virulence of microbial pathogens. In vitro studies have shown that culture media containing 
recombinant lipocalin 2 could inhibit the growth of both E. coli and M. tuberculosis [231, 234, 
236] . Furthermore, lipocalin 2 knockout mice also display increased tissue bacteria numbers 
and mortality in response to E. coli and M. tuberculosis infections [234, 237]. Lipocalin 2 
exerts selective bacteriostatic pressure on pathogenic bacteria, since several pathogenic 
bacteria have developed lipocalin 2 resistance mechanisms to maintain a parasitic relationship 
with the host. These mechanisms include producing multiple and/or modified siderophores to 
escape the inhibitory activity of lipocalin 2 [230, 238, 239]. Lipocalin 2 can also bind to 
endogenous ligands including urinary catechol and its relative 2,5-dihydroxybenzoic acid, 
which indicates lipocalin 2 may sequester host systemic free iron within these complexes to 
limit its availability to pathogens [62, 240]. Beside its role in innate immunity, lipocalin 2 has 
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been shown to also be involved in a range of other biological processes, such as neoplasia, 
kidney development and repair, implantation and involution of the uterus and mammary gland, 
possibly through iron-delivery to certain types of cells[241-245]. However, studies in lipocalin 
2-deficient mice showed no obvious defects in these biological processes, indicating that 
lipocalin 2 function in these biological processes may be redundant [234].  
 
Compared to the fast response of innate immunity, it takes more time (days to weeks) to 
develop adaptive immunity. Adaptive immunity involves the proliferation and differentiation 
of antigen-specific B and T lymphocytes that are required for the antibody- and cell-mediated 
responses, respectively. The implication of iron in adaptive immunity is mainly due to its 
proliferative effect on immune cells and its interference with cell-mediated immune effector 
pathways and cytokine activities. The development of lymphocytes depends on their ability to 
obtain iron via TfR1, also known to immunologists as the differentiation marker CD71. 
Studies indicate that iron deficiency may alter the cytokine expression profile of activated 
lymphocytes, resulting in higher expression of IFN-γ and lower expression of IL-4 [246]. An 
interesting observation that remains to be fully understood is that the number of circulating 
lymphocytes, especially CD8+ T cells, is decreased in patients with HFE-associated HH [247, 
248]. Finally, Hfe-deficiency in mice has been associated with altered cytokine production 
[249, 250].  
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5. Disorders of iron metabolism 
Since iron is bioactive and excess free iron is toxic in the body, conditions resulting in 
excessive iron accumulation and overload in body tissues may cause serious damage. Iron 
overload may result from inherited (primary) and acquired (secondary) causes. Inherited iron 
overload is caused by genetic disorders of iron metabolism that lead to excessive absorption of 
dietary iron and/or impaired iron transport within the body, such as HH [251]. Acquired iron 
overload is often related to the conditions that bypass normal iron absorption and metabolism 
pathways, such as repeated blood transfusions or high doses of supplemental iron, and may be 
aggravated by increased dietary iron absorption in response to inefficient erythropoiesis, as 
seen in β-thalassemia major[252, 253] . A list of causes of iron overload disorders is presented 
in Table 1. 
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Table 1 Causes of iron overload disorders 
 
Category  Condition 
Primary iron overload 
 
 
Hereditary disorders of iron metabolism  
 Hemochromatosis 
 Hypotransferrinemia/atransferrinemia 
 Aceruloplasminemia 
 
Secondary iron 
overload 
Prolonged ingestion of iron-containing supplements 
Excess parenteral iron supplements 
Chronic transfusion therapy 
 -thalassemia major 
 sickle cell anemia 
 myelodysplastic syndromes 
 Diamond-Blackfan anemia 
 marrow replacement 
 maintenance chemotherapy  
 myeloablative hematopoietic stem cell transplantation 
 hemolytic anemias 
 RBC membrane defects 
 RBC enzyme abnormalities 
 hemoglobin molecule defects 
Adapted from [254] 
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5.1 Hereditary hemochromatosis 
The most common form of inherited iron overload is HH [251, 255]. HH is an autosomal 
recessive disorder characterized by excessive intestinal absorption of dietary iron leading to 
progressive and pathological increases in total body iron stores. Excess iron accumulates in 
parenchymal cells of vital organs, primarily in the liver, leading to organ damage. In the early 
stage of the disease, the signs and symptoms of iron overload are nonspecific. They may 
include a wide range of common symptoms such as chronic fatigue, joint pain, impotence, 
osteoporosis, non-specific abdominal problems, and cardiac problems [256, 257]. In the 
advanced stages of the disease, symptoms are more typical, and may include diabetes, 
bronzing of the skin, hepatomegaly, and arthropathy, especially of the second and third meta-
carpophalangeal joints.  
 
Classical HH is caused by mutations in the HFE gene [258]. Almost 10% of the Caucasian 
population carries the most prevalent C282Y HFE mutation, however disease penetrance is 
much lower: 2 to 38% among men and 1 to 10% among women [259]. The C282Y mutation in 
the HFE gene appears to have originated in central Europe [260]. Migration of Europeans to 
USA, Canada, South Africa, and Australia accounts for the high prevalence of HH in these 
countries [261]. The heterozygosity of the H63D mutation combined with heterozygosity of 
the C282Y mutation in the HFE gene may also cause iron overload [257]. Unlike the low 
disease penetrance of HFE gene mutation, loss of functions of HJV, hepcidin, TfR2, and FPN 
result in hemochromatosis. These forms of hemochromatosis are defined by numbers (type 2, 
type 3 and type 4).  Type 2 HH, also called juvenile hemochromatosis (JH), results from 
mutations in genes encoding HJV or hepcidin (in rare cases), and is characterized by the early 
onset of clinical complications [149, 262]. Type 3 HH is caused by TFR2 mutations and shows 
a more severe form of HH with an earlier presentation [196, 263]. Combined mutations of 
HFE and TFR2 also present JH phenotypes [264]. Type 4 HH, also called ‘ferroportin disease’, 
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results from mutations of the ferroportin gene [265, 266]. It has distinct genetic, biochemical, 
clinical and histological features from hemochromatosis [267]. 
 
In mice, deletion of the iron hormone hepcidin and any of genes that regulate its biology, 
including Hjv[145, 148], Bmp6 [187, 188], Hfe [144], TfR2[146] , Smad4[184] , neogenin 
[268], C/EBP alpha [269], and Fpn all lead to reduced hepcidin synthesis (except Fpn) and 
systemic iron overload that resembles human hemochromatosis. 
 
The most common treatment of HH is phlebotomy. Iron removal by regular phlebotomies can 
reverse fibrosis in the liver and cardiomyopathy, as well as improve symptoms such as fatigue 
and skin pigmentation [256, 270, 271]. The major side effects of phlebotomy treatments are 
problems with venous access and the time consuming nature of the treatment [272]. An 
alternative therapy of phlebotomy is therapeutic erythrocytapheresis, which is the removal of 
erythrocytes only instead of whole blood removal. Compared to phlebotomy, it reduces the 
bleeding volume, increases iron removal per session and reduces side effects [273]. Iron 
chelation is another routine therapy. However, it is more expensive and has more severe 
adverse side effects. It is mainly used when phlebotomies cannot be performed, either because 
venous access cannot be obtained, and in patients with heart failure or iron-loading anemia. 
Alcohol consumption should be limited since alcohol has toxic effects on the liver and may 
further suppress hepcidin expression [270, 274].  
 
5.2 β-thalassemia 
-thalassemia syndromes are a group of hereditary blood disorders characterized by defects in 
hemoglobin -chain synthesis, resulting in reduced hemoglobin in RBC, decreased RBC 
production and anemia [275]. -thalassemia is one of the most common autosomal recessive 
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disorders in humans; it affects multiple organs and is associated with considerable morbidity 
and mortality. About 1.5% of the world’s population may be carriers of β-thalassemia and 
about 60 000 infants are born every year with the severe form of the disease [276]. High 
prevalence is present in populations in the Mediterranean area, the Middle East, the Indian 
subcontinent, the Far East and in tropical Africa. Intensive epidemiological and 
case-controlled studies strongly suggest that the high gene frequency of -thalassemia in these 
regions is most likely related to the selective pressure from Plasmodium falciparum malaria, 
since -thalassemia carriers have a survival advantage against the invasion of Plasmodium 
falciparum [277]. Because of population migration, -thalassemia is also present in 
populations in Northern Europe, North and South America, the Caribbean, and Australia. 
 
In adult humans, about 97% of hemoglobins contain 2- and 2-globin chains (2, 2), 
combined with the heme moiety, which has the ability to bind oxygen [278]. At each stage of 
development, the production of α- and β- globins is balanced. In -thalassemia, mutations in 
the -globin gene abolish or reduce the synthesis of -globin chains, which result in 
imbalanced production of α- and β- globins. Relative excess -globin chains accumulate in 
erythroid precursors, resulting in their premature death and in ineffective erythropoiesis [279]. 
At the molecular level, -thalassemia-related mutations are heterogeneous. So far, more than 
200 different mutations have been identified in the disease. The majority of mutations are 
point mutations or small insertions or deletions of a few bases [280, 281]. Rarely, 
-thalassemia can result from gross gene deletion involving part of or the whole -globin gene. 
Point mutations influence -globin expression at three different levels: gene transcription, 
mRNA processing and mRNA translation.  
 
The severity of -thalassemia depends partly on the extent of the reduction of -chain output. 
Clinical expression can thus be severe, mild or silent. Nevertheless, individuals with identical 
mutations in β-globin genes may present very different phenotypes, ranging from mild to 
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severe. The clinical phenotype of -thalassemia includes thalassemia major, thalassemia 
intermedia, thalassemia minor, dominant -thalassemia and -thalassemia associated with 
other hemoglobin anomalies [282]. Thalassemia major develops in homozygotes or compound 
heterozygous mutation carriers.  
 
Anemia in patients with -thalassemia requires periodic blood transfusions, leading to 
excessive iron accumulation in the body (secondary hemochromatosis). Therefore, monitoring 
iron status is crucial in thalassemia patients, since it helps evaluate the clinical relevance of 
iron overload, the need for treatment, and the timing and monitoring of chelation therapy. 
Iron-chelators bind to excess iron in the body, which allows iron exit through urine and stool. 
In general, after 10-12 transfusions, or when ferritin levels rise above 1000 ng/ml, patients 
begin iron chelation therapy [283]. The first drug available for chelation therapy was 
deferoxamine (DFO). The most common side effects of DFO are local reactions at the site of 
infusion, such as pain, swelling, induration, erythema, burning, pruritus, wheals and rash. 
However, treatment with DFO significantly reduces the morbidity and mortality of 
-thalassemia. Two other chelators deferiprone (DFP) and deferasirox (DFX) are also 
available for clinical use. DFP is a bidentated oral chelator. DFP combined with DFO could 
achieve levels of iron excretion that cannot be achieved by either drug alone without 
increasing toxicity [284, 285]. The side effects include neutropenia, agranulocytosis, 
arthropathy, and gastrointestinal symptoms which demand close monitoring [282].  
 
Bone marrow transplantation (BMT) from an HLA-identical sibling is the definitive cure 
currently available for patients with -thalassemia. The outcome of BMT is related to 
pretransplantation clinical conditions, specifically the presence of hepatomegaly, extent of 
liver fibrosis, history of regular chelation and hence the magnitude of iron accumulation. A 
lower survival rate is correlated with the presence of these risk factors. About 5–8% of 
patients develop chronic graft-versus-host disease (GVHD) with variable severity. The major 
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issue of allogenic BMT is the lack of an HLA-identical sibling donor for the majority of 
affected patients. Cord blood transplantation from a related donor offers a good alternative and 
is associated with a low risk of GVHD.  
 
5.3 Anemia of chronic diseases 
The anemia of chronic disease (ACD), also termed anemia of inflammation, is the most 
prevalent anemia in hospitalized patients worldwide and the second most prevalent worldwide 
anemia after iron deficiency [286]. ACD often develops in the setting of chronic disease, 
infections or malignancy. The hallmark of ACD is that body iron stores can be normal or even 
high, but the iron available for erythropoiesis is very much restricted [286-288]. Anemia 
develops due to the impaired mobilization of iron from diet and stores rather than inadequate 
iron intake. ACD is classically mild-to-moderate anemia (Hgb 70–120 g/L) and the symptoms 
may include: weakness and fatigue, headaches, paleness and shortness of breath. The 
development of anemia is associated with detrimental effects especially in relation to cardiac 
function, quality of life, growth and mental development [289]. Strong evidence has suggested 
that ACD has a negative impact on the quality of the life and that ACD can independently 
worsen morbidity and mortality of many disorders [290, 291]. However, hypoferremia and 
iron restriction in the circulation may also have some potentially positive effects, especially 
for patients with cancer and infectious diseases [292]. Three major pathophysiological 
mechanisms, all related to immune system activation, have been identified so far as underlying 
ACD.  
 
One of the mechanisms involves decreased erythrocyte lifespan. Early studies suggest that 
transfused ACD erythrocytes have a normal lifespan in normal recipients but transfused 
normal erythrocytes have a decreased lifespan in ACD recipients [293]. The decreased 
lifespan is related to the activation of macrophages, which prematurely removes aging 
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erythrocytes from the blood stream. In addition, the increased production of cytokines, such as 
IFN-γ, IFN-α, TNF-α and IL-1, can inhibit the proliferation and differentiation of erythroid 
progenitor cells [294, 295]. Several other factors, such as the cytokine-mediated 
down-regulation of EPO-receptor expression on progenitor cells and direct toxic effects of 
cytokine-inducible radicals, also contributes to the inhibition of erythroid progenitor cell 
proliferation [296]. Finally, acute-phase proteins, such as α1-antitrypsin and α2-macroglobulin, 
also can play a role by suppressing the growth and differentiation of erythroid progenitor cells 
via inhibiting iron uptake [297, 298].  
 
A second mechanism is linked to suboptimal EPO activity resulting from diminished EPO 
production and blunted response to EPO. Often, EPO levels in ACD patients are well below 
the expected range based on the degree of anemia [288, 299]. Inflammatory cytokines such as 
IL-1 and TNF- have been shown to inhibit EPO gene expression in vitro [300], mainly 
through increased binding activity of inflammatory cytokines to the transcription factor GATA 
and resulting inhibition of EPO gene promoter activity [301]. In addition, IL-1 and TNF-α also 
induce toxic radicals that damage EPO-producing cells [300].  
 
The third and most important mechanism involves iron-restricted erythropoiesis. Under 
inflammatory conditions, pro-inflammatory cytokines, such as TNF-α can increase iron levels 
in monocytes/macrophages through transcriptional induction of ferritin expression [302, 303]. 
The mechanism of increased iron accumulation by RES is additionally related to the 
stimulation of erythrophagocytosis by macrophages. Studies have shown that TNF-α leads to 
shortening of erythrocyte half-life and faster clearance of these cells via erythrophagocytosis 
[304]. Another cytokine, IFN-γ, also affects iron storage in monocytes/macrophages as it 
modulates ferritin transcription and translation via nitric oxide (NO) formation. NO induction 
by IFN-γ depends on the iron status of cells, resulting in either stabilization or degradation of 
ferritin via IRE and IRP2 activity modulation [305-310]. Cytokines also can directly 
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down-regulate ferritin transcription, leading to blockage of iron export from macrophages. 
Last but not least, hepcidin released by monocytes/macrophages during inflammation targets 
ferroportin in an autocrine fashion, further promoting iron retention in these cells [138, 311, 
312]. Summarizing, cytokines promote iron accumulation and retention within macrophages 
via stimulation of various iron acquisition pathways and hepcidin induction. While iron 
retention in macrophages results in limited iron availability to pathogens, thus functioning as a 
defense mechanism of the immune system against invading pathogens, this innate immune 
response also results in limited iron availability to the fundamental process of erythropoiesis, 
and in the development of ACD.  
 
The severity of anemia is related to the underlying disease process. Thus, initial treatment 
should be concentrated on the causative disease. This is often sufficient if the symptom is mild 
or asymptomatic. For patients with severe anemia or with diseases which can't be reversed, 
such as chronic kidney disease or patients with cancer being treated by chemotherapy, 
alternative strategies, such as transfusion, erythropoiesis-stimulating agents (ESAs), iron 
supplementation and blocking the inflammatory responses, are often necessary.  
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6. Rational and objectives of study 
The first objective of this thesis is linked to the observation that, in HH, excessive 
non-transferrin-bound iron (NTBI) is cleared from the circulation and deposited into 
hepatocytes. At the molecular level, iron-transporter molecules that may be responsible for 
iron uptake into hepatocytes in these conditions remain elusive. Lcn2, an acute phase protein 
[234, 243, 313, 314], is known to be involved in iron trafficking via siderophores [62, 240]. 
Once Lcn2 is bound to iron-laden siderophores, it serves as an iron donor; conversely, 
iron-free Lcn2-siderophores function as iron chelators [315, 316]. Thus, Lcn2 has emerged as 
a candidate iron-transporter, which may be responsible for NTBI accumulation in the liver of 
HH patients. Hence, the first objective of this study is to evaluate the importance of Lcn2 in 
the pathogenesis of hepatic iron loading in Hfe knockout mice. To this end, HfeLcn2 
double-knockout mice will be generated and phenotyped in regards to iron metabolism 
(Chapter 2).  
 
As mentioned before, hepcidin expression is induced by iron-loading and inflammation while, 
conversely, being inhibited by anemia and hypoxia. Under certain pathologic situations, 
hepcidin is regulated by more than one regulator that modulates hepcidin expression in 
opposing directions. For example, in ACD, hepcidin is co-regulated by anemia (inhibitory 
effect) and inflammation (stimulatory effect). In iron-loading anemias, disorders characterized 
by increased inefficient erythropoiesis, such as -thalassemia, hepcidin is regulated by both 
anemia (inhibitory effect) and iron-loading (stimulatory effect). Despite intensive research into 
hepcidin regulation over the last decade, hepcidin regulation by opposing stimuli remains 
poorly understood. The second objective of my thesis is therefore to investigate how different 
factors influence hepcidin expression in vivo. To this end, hepcidin regulation in the presence 
of opposing stimuli as well as the contributions of mediators and downstream signaling 
pathways of hepcidin expression will be examined in vivo in mouse models (Chapter 3). 
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Abstract 
 
 
 
Under normal conditions, iron is taken up by the cells through the transferrin-mediated 
pathway. However, in hereditary hemochromatosis, a common iron-overloading disorder 
associated with mutations in the HFE gene, iron in plasma exceeds transferrin-binding 
capacity, and non-transferrin-bound iron appears in the circulation of patients with iron 
overload. This non-transferrin-bound iron can be taken up by hepatocytes through a 
transferrin-independent pathway. Lipocalin 2 (Lcn2), a secreted protein of the lipocalin family, 
has emerged as the mediator of an alternative, transferrin-independent pathway for cellular 
iron delivery. To evaluate the importance
 
of Lcn2 in the pathogenesis of hepatic iron loading in 
Hfe knockout
 
mice, we generated HfeLcn2 double-deficient mice. Our studies revealed that 
deletion of Lcn2 in Hfe-knockout mice does not influence hepatic iron accumulation in Hfe
-/-
 
mice, or their response to iron loading, as the phenotype of HfeLcn2
-/-
 mice remained 
indistinguishable from that of Hfe
-/-
 mice. We conclude that Lcn2 is not essential for iron delivery 
to hepatocytes in hemochromatosis. 
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Introduction 
Under
 
normal conditions, the major pathway for cellular iron uptake is through 
internalization of the complex of iron-bound transferrin and the transferrin receptor. Thereafter, 
iron is released from transferrin as the result of acidic pH in endosomes and is transported to 
the cytosol by divalent metal ion transporter 1 (DMT1; also known as SLC11A2)[30, 317].  
However, there is convincing evidence that, in situations of disrupted iron homeostasis, iron 
can also be delivered to cells by alternative, transferrin-independent mechanisms. For example, 
mice and humans lacking transferrin, while anemic, develop iron overload in the liver, 
implicating that iron is being delivered to hepatocytes by transferrin-independent pathway(s) 
[318, 319]. Likewise, in HFE-related hereditary hemochromatosis (HH), a common disorder 
of iron homeostasis characterized by excessive iron deposition principally in the liver [320, 
321], iron overload exceeds the iron-binding capacity of serum transferrin [38, 106] , and this 
non-transferrin-bound iron (NTBI) is cleared from the circulation and deposited into 
hepatocytes [322]. This alternate iron uptake pathway is further brought into evidence by 
studies in Dmt1
–/– 
knockout mice [323]. In fact, despite the presence of a disrupted transferrin 
cycle, Dmt1
-/-
 mice have
 
abnormally high iron liver stores. Moreover, iron-loading with iron 
dextran leads to significant accumulation of iron in Dmt1
-/-
 hepatocytes, further indicating that 
the liver has alternate mechanisms than the transferrin cycle for iron uptake [323]. The 
identification of the components
 
of NTBI however, remains elusive.  
 
Lipocalin 2 (Lcn2), also called neutrophil gelatinase-associated lipocalin (NGAL) or 
24p3 [324], has been proposed to be a mediator of the transferrin-independent iron delivery 
pathway [325] after it was found that Lcn2 can bind bacterial ferric siderophores [326], and 
that  Lcn2-siderophore-iron complexes can transport iron into cells during kidney 
development [327].  
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Lcn2 has been found to exert a broad range of biological activities, which seems to depend 
on whether Lcn2 is bound to iron-laden siderophores  or not,  implicating iron-loaded 
Lcn2-siderophore as an iron donor
 
and, conversely, iron-free Lcn2-siderophore as an iron 
chelator [328, 329]. 
 
As such, iron-loaded Lcn2-siderophore (Holo-Lcn2) has been shown to 
be required for mesenchymal-epithelial transition of embryonic kidney [327] and oncogene 
Ras-transformed epithelial cells [330], as well as for kidney protection from renal failure [331, 
332], and delivery of ferric ion to mouse spermatozoa [333]. In contrast, Lcn2–siderophore 
complex without iron [334] and Lcn2 (Apo-Lcn2) [241] chelates iron from cells and, through 
iron deprivation, can induce apoptosis of pro-B cells, [241] and inhibit bacterial growth [326, 
335, 336] and erythropoiesis [337, 338]. Additional evidence that Lcn2 may assist cellular iron 
trafficking is provided by the demonstration that iron delivered through Lcn2 has been shown 
to regulate iron-sensitive genes [334] and the identification of one of its receptors as being 
megalin [339]. Megalin is also known to bind another iron-binding protein, namely lactoferrin 
[340, 341]. Thus, Lcn2 emerged as a possible candidate involved in NTBI uptake under 
iron-overload conditions and, as such, possibly implicated in the pathophysiology of HH [325, 
342]. 
 
In this report we investigated whether Lcn2, as a component of an alternative iron delivery 
system, may contribute to the pathophysiology of HH. For this purpose, we generated and then 
characterized iron metabolism in HfeLcn2-double mutant mice. 
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Materials and Methods  
Animals. All procedures were performed in accordance with Canadian Council on Animal 
Care guidelines and approved by the institutional Animal Care Committee. Control, wild-type 
mice were C57BL/6 female mice purchased from Charles River Laboratories, Inc. 
(Wilmington, MA). Hfe
-/-
 mice were kindly provided by Dr. Nancy C. Andrews, Howard 
Hughes Medical Institute and Harvard Medical School, Children's Hospital, Boston, MA, USA 
[343], in the 129/SvEvTac background, and were backcrossed onto the C57BL/6 (B6) 
background for 10 generations [344]. Lcn2
-/- 
mice generated in the C57BL/6
 
(B6)
 
background 
have been described previously [335]. Compound mutants, HfeLcn2
-/-
,
 
were obtained by 
interbreeding Hfe
-/-
 and Lcn2
-/- 
mice and genotyped by PCR (supplementary Figure 1A and B). 
The following primers were used: Hfe - 5’-AGTTGGGAGTGGTGTCCGA-3’; 
5’-TGGCTACAGTGTGAGAGGC-3’ and 5’ CTAGCTTCGGCCGTGACG-3’; Lcn2 - 
5’-CCTCAAGGACGACAACATCA-3’; 5’-ACCCATTCAGTTGTCAATGC-3’;  
5’-TTGGGTGGAGAGGCTATTC-3’ and 5’-AGGTGAGATGACAGGAGATC-3’. All mice 
used in the experiments were genotyped by PCR assay performed on DNA prepared from 
mouse tails. Absence of Lcn2 expression in Lcn2
-/- 
and HfeLcn2
-/-
 mice was confirmed by 
western blotting, using a monoclonal anti-mouse Lipocalin-2/NGAL antibody (R&D Systems 
Inc. Minneapolis, MN) (supplementary Figure 1C). 
 
Diets. Mice were given a commercial diet (Harlan Teklad, Madison, WI), or, when 
indicated, an iron-supplemented
 
diet containing 2.5% (w/w) carbonyl iron (Sigma 
Immunochemicals,
 
St. Louis, MO).  
Measurement of serum iron, transferrin saturation, and tissue iron concentration. Serum 
iron, total iron-binding capacity and transferrin saturation were assessed by colorimetric assay 
 64 
[345]. Iron levels in livers, spleens, heart and kidneys were measured by acid digestion
 
of 
tissue samples followed by iron quantification by atomic absorption
 
spectroscopy [345].  
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Total RNA
 
was 
isolated with Trizol reagent (Invitrogen, Burlington, ON, Canada), and RT was performed with 
the Thermoscript RT-PCR system (Invitrogen). Hepcidin 1 (Hamp 1) and -actin mRNA 
levels were measured by real-time PCR in a Rotor Gene 3000
TM
 Real Time DNA Detection 
System (Montreal Biotech Inc., Kirkland, QC, Canada) with the QuantiTect SYBRGreen I 
PCR kit (Qiagen, Mississauga, ON, Canada), as described [345], and expression levels of 
hepcidin were normalized to the housekeeping gene -actin. The primers employed were:  
-actin – 5’-TGTTACCAACTGGGACGACA-3’ and 5’-GGTGTTGAAGGTCTCAAA-3’; 
Hamp 1 – 5’AGAGCTGCAGCCTTTGCAC3’ and 5’GAAGATGCAGATGGGGAAGT3’.  
 
Statistical analysis.  All statistics were calculated using SigmaStat® 3.1 (Systat Software, 
Richmond, CA). All values in the figures are expressed as means ± SD. Multiple comparisons 
were evaluated statistically by 1-way analysis of variance (ANOVA), followed by the 
Bonferroni multiple comparison test. 
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Results 
Hfe
-/-
 mice develop iron overload characterized by high circulating iron levels and 
deposition of excess iron in the liver, but with resistance to iron loading in the spleen due to 
deficient iron storage in macrophages [343]. To determine whether Lcn2 participates in iron 
delivery to the liver in Hfe-deficient mice, we interbred Hfe
–/–
 and Lcn2
-/-
 mice. Circulating 
iron levels, assessed by measuring serum iron and transferrin saturation, as well as iron 
deposition in the liver and spleen were analyzed at 10 and 20 weeks of age (Figure 1). Iron 
parameters in Lcn2-single knockout mice were similar to those in wild-type mice (B6), while 
Hfe
-/-
 and HfeLcn2-double mutants had higher amounts of circulating and liver iron  than B6 
mice (~1.5-2-fold higher; P < 0.05; Figure 1A-1C). In contrast, spleen iron content, while 
slightly increased with age, was lower in 10-week-old Hfe
-/-
 and HfeLcn2
-/- 
mice compared to 
B6 (31% lower; P < 0.05) or Lcn2
-/-
 mice (Figure 1D). No significant differences were found in 
heart iron (Figure 1E), while iron levels in kidneys were slightly increased in both, Hfe
-/-
 and 
HfeLcn2
-/- 
mice, compared to B6 mice (Figure 1F). Thus, we found no significant differences 
between Hfe
-/-
 and HfeLcn2
-/- 
mice regarding iron parameters. These results indicate that iron 
accumulation in the liver of Hfe
-/-
 mice did not improve in the absence of Lcn2, suggesting 
that Lcn2-mediated cellular iron delivery is not essential in iron uptake by the liver in Hfe
-/-
 
mice.  
 
To further investigate the responses to dietary iron loading in compound mutants, we 
challenged the mice with a 2.5% wt/wt carbonyl iron-supplemented diet for 2 weeks (Figure 2). 
B6 and Lcn2
-/-
 mice fed the iron-enriched diet showed significant increments of serum iron, 
transferrin saturation (>50% increase; P < 0.01), hepatic iron content (>4-fold rise; P < 0.001) 
and spleen iron content (>2.5-fold elevation; P < 0.001) compared to mice on the control diet 
(Figure 2A-2C). While Hfe
-/-
 and HfeLcn2
-/- 
double knockout mice also manifested heightened 
liver iron content over the already-elevated levels observed on the control diet in response to 
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dietary iron loading (>2-fold rise; P < 0.001), the increase in iron loading of the spleen was 
considerably more modest than what was seen in B6 (P < 0.01) or Lcn2
-/-
 mice on the 
iron-supplemented diet (Figure 2D).  
 
Because augmented iron absorption in Hfe
-/-
 mice has been related to inappropriate 
expression levels of hepcidin [144], the principal regulator of systemic iron homeostasis, we 
also measured hepatic hepcidin 1 mRNA. As illustrated in Figure 2E, we found lower amounts 
of hepcidin in both Hfe
-/-
 and HfeLcn2-double mutants than in B6 and Lcn2
-/-
 mice on the 
control diet (~30% decrease). Hepcidin levels rose about 2.5-3.5-fold in response to iron 
loading in all mouse strains (P < 0.01), but remained significantly lower in Hfe
-/-
 and 
HfeLcn2
--/-
 mice compared to B6 (P < 0.05) or Lcn2
-/-
 mice. Since the response to iron-loading 
was indistinguishable between Hfe
-/-
 and HfeLcn2
--/-
 mice, these results further confirm that 
Lcn2 is not essential for iron delivery to the liver and the regulation of hepcidin in HH. 
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Discussion 
 
While under normal conditions hepatocytes acquire iron mostly through the 
transferrin-receptor pathway, the existence of uptake of NTBI in HH is now well established. 
Several candidates have been proposed, including Lcn2, but clear demonstration of its 
participation and importance in HH has not been yet provided. 
  
 
In this report, we set out to determine whether Lcn2 represents a physiologically-relevant 
mechanism of iron uptake by the liver in HH, an iron overloading disease. For this purpose, 
we generated and characterized iron metabolism in HfeLcn2-double knockout mice. The Hfe
-/-
 
mice have increased plasma NTBI levels and, importantly, hepatocytes from Hfe
-/-
 mice have 
been shown to uptake significantly more NTBI than control
 
mice [38]. We found that basal 
iron status and iron metabolism changes induced by iron diet supplementation were 
indistinguishable between Hfe-single knockout and HfeLcn2-double knockout mice. Our 
results indicate that Lcn2 is dispensable for NTBI uptake by hepatocytes in HH. However, 
they do not exclude that the Lcn2-mediated iron delivery pathway may be involved in other 
pathologies.  
 
The identification of the components of non-transferrin bound  iron delivery pathways 
remains important for the understanding of the patophysiology of HH and other iron overload 
diseases such as hypotransferrinemia and
 
thalassemia, because in these situations plasma iron 
exceeds the binding capacity of transferrin  and uptake of non-transferrin bound  iron  
significantly contributes to  iron accumulation in the liver, pancreas and heart [346]. 
Non-transferrin-bound iron uptake mechanism  have been described in a variety of cell 
lines [347, 348], including hepatocytes [349].  In hepatocytes, this system requires the 
reduction of Fe
3+
 to Fe
2+ 
[349].  Iron salts, such as iron
 
ascorbate, citrate, or nitrilotriacetate 
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have been suggested as candidates for low-molecular-weight non-transferrin iron carriers, but 
the transporter(s) of non–transferrin-bound iron remains to be identified. Beside Lcn2, which 
the present study suggests it is redundant, potential candidates include L-type 
voltage-dependent Ca2+ channels (LVDCCs) [350] and Zip14 [351] . 
LVDCCs have been identified as key transporters of iron into cardiomyocytes and 
neuronal cells under iron-overload conditions [350, 352]. Further support for a role for cardiac 
LVDCCs in myocardial non-transferrin bound iron uptake under conditions of iron overload 
comes from the demonstration that LVDCCs blockers are protective and able to attenuate 
myocardial iron accumulation in iron-overloaded mice [353].  
Zip14 is a zinc transporter and member of the SLC39A metal ion transporter family [354], 
and is highly expressed in hepatocytes. Recent studies have shown that mouse
 
Zip14 
transports both iron and zinc in cultured hepatocytes [351].  
In conclusion, the work presented here shows that Lcn2 is dispensable for iron delivery to 
hepatocytes in the context of Hfe-deficiency. Further studies will be necessary to establish 
whether other candidates, namely LVDCCs and Zip14, are involved in the uptake of 
non-transferrin-bound iron by hepatocytes under iron-overload conditions such as HH.  
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Figures and Legends 
 
Figure 1. Iron parameters in 10 week-old and 20 week-old wild-type (B6) and mutant 
mice. Serum iron (A), transferrin saturation (B), iron concentration in the liver (C), spleen (D), 
heart (E) and kidney (F). The results are presented as means ± SD from n=6-8 mice per group. 
(*, P < 0.05;  **,  P < 0.01, ***,  P < 0.001 and mutant mice versus B6 same age). 
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Figure 2. Response to iron-loading in wild-type (B6) and mutant mice. Serum iron (A), 
transferrin saturation (B), iron concentration in the liver (C) and spleen (D) and hepatic 
hepcidin 1 mRNA expression (Hamp 1) (E) in mice on a standard diet (light-shaded bars) and 
mice on a diet supplemented with 2.5% carbonyl iron for 2 weeks (dark-shaded bars). The 
results are presented as means ± SD from n=6-8 mice per group. (##, P < 0.001 mutant mice 
versus B6; *, P < 0.01 and **, P < 0.001 iron-supplemented versus standard diet). 
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Supplementary Figure 1 (A and B) Mouse genotyping using genomic DNA extracted from 
mouse tails and the primers described in materials and methods. (C) Immunoblot analysis of 
kidney protein extracts using a monoclonal anti-lipocalin 2 antibody. 
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In chapter 2 we evaluated the importance of Lcn2 in the pathogenesis of hepatic iron loading 
in Hfe knockout
 
mice. We conclude that Lcn2 is dispensable for iron delivery to hepatocytes in 
the context of Hfe-deficiency. As mentioned before, at the site of inflammation/infection, Lcn2 
is released by neutrophils to sequester bacterial ferric siderophores. Lcn2 comprises a critical 
component of innate immunity to exogenous bacterial infections. Hepcidin, stimulated by 
inflammation, by inducing sequestration of iron in macrophages, and limiting iron uptake from 
gut, robs bacteria of this element. Therefore, both Lcn2 and hepcidin, sequester iron, but via 
different mechanisms, as part of host defense mechanisms. The regulation of hepcidin has 
been studied extensively. In the next chapter, we will further investigate hepcidin regulation by 
opposing stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
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Hepcidin, a key regulator of iron metabolism, is a small antimicrobial peptide produced by 
the liver that regulates intestinal iron absorption and iron recycling by macrophages. Hepcidin 
is stimulated when iron stores increase and during inflammation, and, conversely, is inhibited 
by hypoxia and augmented erythropoiesis. In many pathological situations, such as in the 
anemia of chronic disease (ACD) and iron-loading anemias, several of these factors may be 
present concomitantly and may generate opposing signaling to regulate hepcidin expression. 
Here, we addressed the question of dominance among the regulators of hepcidin expression. 
We show that erythropoiesis drive, stimulated by erythropoietin but not hypoxia, 
down-regulates hepcidin in a dose-dependent manner, even in the presence of 
lipopolysaccharide (LPS) or dietary iron-loading, which may act additively. These effects are 
mediated through down-regulation of phosporylation of Stat3 triggered by LPS and of 
Smad1/5/8 induced by iron.  
 
 
In conclusion, hepcidin expression levels in the presence of opposing signaling are 
determined by the strength of the individual stimuli rather than by an absolute hierarchy 
among signaling pathways. Our findings also suggest that erythropoietic drive can inhibit both 
inflammatory and iron-sensing pathways, at least in part, via the suppression of STAT3 and 
SMAD4 signaling in vivo.  
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Introduction 
 
Body iron stores are kept in balance by controlling the level of absorption from the diet, 
because in mammals iron is not efficiently excreted [355]. Thus, considerable work in the past 
was directed at identifying factors that influence intestinal iron absorption. Those studies 
established that both the size of iron stores and the rate of erythropoiesis influence the amount 
of iron being absorbed in the intestine [356]. Information about the amount of iron in the body 
is transmitted to the intestine where iron absorption takes place such that, if the body is 
iron-depleted, the amount of daily iron absorption is augmented, whereas if there is an excess 
of iron, absorption is diminished to prevent iron-overloading (referred to as the store 
regulator). Iron absorption is also independently regulated by erythropoiesis: it increases when 
erythropoietic activity rises (erythroid regulator) [356]. Additional systemic stimuli that also 
affect intestinal iron absorption include tissue oxygenation (hypoxia regulator) [357], and 
inflammatory cytokines (inflammatory regulator)[358]. During hypoxia, iron absorption 
increases [359], while, conversely, it may decline during inflammation [358]. 
 
 More recent work identified hepcidin, a small antimicrobial peptide [360, 361], as an effector 
molecule common to all these four regulators of iron absorption [362, 363]. Hepcidin 
expression is stimulated when iron stores increase [362] as well as during inflammation [363]. 
Conversely, it is inhibited by anemia/hypoxia and heightened erythropoiesis drive [363, 364].   
 
In many pathological situations however, antagonistic signaling for hepcidin regulation can 
co-occur. For example, anemia may co-occur with inflammation, as seen in the anemia of 
chronic disease (ACD) [365] arising in chronic inflammatory conditions such as autoimmune 
diseases, chronic infectious diseases and cancer. ACD is associated with excessive production 
of cytokines produced by macrophages and T-lymphocytes which ultimately leads to iron 
 77 
withdrawal from circulation and iron sequestration in reticuloendothelial macrophages and 
thus, to impaired iron mobilization from stores [365]. This may explain why patients with 
ACD may become iron-deficient when inhibition of intestinal iron absorption by high hepcidin 
levels is sustained for a long period.  When treating the underlying disease is not feasible, 
erythropoietin (EPO) agents may help stimulate erythropoiesis and improve hemoglobin levels 
in patients with ACD [365]. However, whether the therapeutic effect of EPO also involves 
suppression of hepcidin expression in inflammatory conditions has not yet been demonstrated. 
Previously, we showed that hepcidin expression is induced in iron-deficient mice after 
lipopolysaccharide (LPS) challenge even in iron-depleted mice [366]. Similarly, in humans 
treated with endotoxin, serum hepcidin levels also increased despite the presence of slightly 
decreased serum iron levels [367].   
 
Anemia may  also co-occur with iron overload as observed in disorders characterized by 
robust but inefficient erythropoiesis [368]. These disorders, collectively called iron-loading 
anemias, include among others: thalassemia syndromes, congenital dyserythropoietic anemias 
and sideroblastic anemias that have ineffective erythropoiesis in common, leading to the 
development of anemia and consequent hypoxia [369]. The second common characteristic of 
these disorders is the development of iron-overload, which can be severe as a consequence of 
inappropriately-increased intestinal iron absorption [356]. Indirect evidence suggests that 
serum factors in -thalassemia patients might override the potential effect of iron-overload on 
hepcidin expression and thus explain the inappropriate intestinal iron absorption levels. In fact, 
serum from -thalassemia individuals has been reported to inhibit hepcidin mRNA expression 
in hepatoma cells [370].  
 
 Because of the central role of hepcidin in iron metabolism and its direct contribution to the 
pathogenesis of several common disorders, it is important to understand how different factors 
influence hepcidin expression in vivo and lead to its misregulation when present concomitantly. 
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In this study we examined how hepcidin is regulated in the presence of opposing stimuli in 
vivo in mice as summarized in Figure 1, and further investigated the contribution of mediators 
and downstream signaling pathways of hepcidin expression. 
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Materials and Methods 
 
Animals  
All procedures were performed in accordance with Canadian Council on Animal Care 
guidelines after approval by the institutional Animal Care Committee of the CRCHUM. 
C57BL/6 female mice aged 6 weeks were purchased from Charles River Laboratories, Inc. 
(Wilmington, MA).   
 
Animal treatments  
Erythroid regulator-Erythropoiesis was induced by treating mice with 50 U of human 
biosynthetic erythropoietin- (EPO) (epoetin alfa, Ortho Biotech, Bridgewater, NJ) dissolved 
in phosphate-buffered saline (PBS). Mice were injected i.p. daily for four days and were 
sacrificed on day 5. Control mice were similarly injected with an equivalent volume of PBS.  
Immune regulator- Acute inflammation was produced by a single dose of lipopolysaccharide 
(LPS, Escherichia coli serotype 055:B5 – 1 mg/kg i.p., Sigma-Aldrich, St. Louis, MO). In 
other experiments, mice were injected with recombinant mouse IL-6 (1 µg i.p., Cederlane 
Laboratories Ltd., Hornby, Ontario, Canada). Control mice were similarly injected with an 
equivalent volume of sterile saline solution (0.09% NaCl). The animals were sacrificed six 
hours after the LPS and three hours after the IL-6 injection.  Stores regulator- Control mice 
were given a commercial diet containing approximately 226 mg of iron per kg (Teklad Global 
18% protein rodent diet, Harlan Teklad, Madison, WI). Dietary iron overload was produced by 
giving 8-week-old mice the same commercial diet supplemented
 
with 25 g carbonyl iron (2.5% 
w/w carbonyl iron from Sigma-Aldrich) for 2 weeks. Hypoxia. Normobaric hypoxia was 
established by diluting ambient air with nitrogen in a special ventilated chamber in which 
N2-enriched air supply was controlled with an O2 sensor-driven inlet valve. Mice were 
maintained in the chamber and exposed to normobaric hypoxia (10% O2) for three days. An 
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oxygen analyzer was used to monitor the oxygen concentration in the hypoxic chamber. 
Age-matched control mice were kept under normoxia (room air) in the same room in which 
the hypoxic chamber was placed. 
 
Hematological measurements and transferrin saturation 
Red blood cell (RBC) count, hemoglobin (Hb), hematocrit (HCT) and mean corpuscular 
volume (MCV) were measured with an automated cell counter calibrated for murine samples 
(ABC vet counter, ABX hématologie, Montpellier, France). Serum iron, total iron-binding 
capacity and transferrin saturation were assessed by colorimetric assay with the Kodak 
Ektachem DT60 system (Johnson & Johnson, Ortho Clinical Diagnostics, Mississauga, ON, 
Canada).  
 
Measurement of tissue iron concentration 
Liver iron concentrations were assessed by acid digestion
 
of tissue samples, followed by iron 
quantification with atomic absorption
 
spectroscopy [371]. 
 
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
Total RNA
 
was isolated with Trizol reagent (Invitrogen, Burlington, ON, Canada), and RT was 
performed with the Thermoscript RT-PCR system (Invitrogen). Hepcidin and -actin mRNA 
levels were measured by real-time PCR in a Rotor Gene 3000
TM
 Real Time DNA Detection 
System (Montreal Biotech Inc., Kirkland, QC, Canada) with QuantiTect SYBRGreen I PCR 
kits (Qiagen, Mississauga, ON, Canada) as described [345]. The primers employed were: 
-actin – 5’-TGTTACCAACTGGGACGACA-3’ and 5’-GGTGTTGAAGGTCTCAAA-3’; 
hepcidin – 5’AGAGCTGCAGCCTTTGCAC3’ and 5’GAAGATGCAGATGGGGAAGT3’; 
IL-6 – 5’TGTGCAATGGCAATTCTGAT3’ and 5’CCAGAGGAAATTTTCAATAGGC3’. 
Expression levels were normalized to the housekeeping gene -actin.  
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IL-6 assay 
IL-6 was measured
 
in serum and in supernatants of liver homogenates with an ELISA kit as
 
per manufacturer’s instructions (mouse IL-6 ELISA kit, catalog # M6000B, R & D Systems, 
Minneapolis,
 
MN). Snap-frozen liver samples were thawed, weighed, and homogenized
 
in 
solutions containing 1 ml of protease inhibitor cocktail
 
(Complete; Boehringer Mannheim, 
Indianapolis, IN). The resulting
 
supernatants were analyzed and standardized to
 
the weight of 
the liver sample. 
 
SDS-polyacrylamide-gel electrophoresis and Western blot analysis 
Livers were removed, rinsed in ice-cold PBS and used to prepare liver nuclear extracts with 
Nuclear Extract Kits (Active Motif, Carlsbad, CA). Nuclear protein extracts were separated on 
10% SDS-polyacrylamide gel and blotted onto nitrocellulose membranes (GE Healthcare, 
Buckinghamshire, UK). The membranes were immunoblotted with the following antibodies: 
phospho-Stat3, Stat3, phospho-Smad1/5/8 (Cell Signaling, Danvers, MA), Smad1/5/8 (Santa 
Cruz Biotechnology, Santa Cruz, CA) and -actin (Abcam, Inc., Cambridge, MA). As a 
secondary antibody, anti-rabbit IgG (Cell Signaling) or anti-mouse IgG (GE Healthcare) were 
used. Antigen-antibody complexes were visualized with the ECL
TM
 Western Blotting 
Detection Reagent (GE Healthcare). 
 
Statistical analysis 
All statistics were calculated with SigmaStat® 3.1 (Systat Software, Richmond, CA). Multiple 
comparisons were evaluated statistically by 1-way analysis of variance (ANOVA) followed by 
the Bonferroni multiple comparison test. When data failed the equal variance test, the 
Kruskal-Wallis 1-way ANOVA on ranks was used followed by Student-Newman-Keuls or 
Dunn’s post hoc test. Correlation coefficients were determined by Spearman’s correlation 
coefficients.  
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Results 
Erythropoietin but not hypoxia blocks hepcidin induction by LPS 
EPO: Previous studies have demonstrated that when erythropoiesis is stimulated by 
erythropoietin (EPO), hepcidin mRNA expression is inhibited [364, 372], and, conversely, 
LPS induces it [362].  To assess whether increased erythropoiesis could affect the induction 
of hepcidin by LPS, mice were treated for four consecutive days with EPO to stimulate 
erythropoiesis, followed by a single injection of LPS on day 5 and were examined after 6 h. 
EPO treatment stimulated erythropoiesis, as revealed by the elevation of hematological indices 
(RBCs – 12.4%; HGB – 11.5% and HCT – 19.9% increase). As shown in Figure 2A, EPO 
alone led to a significant inhibition of mRNA hepcidin expression (92% reduction). When 
compared to LPS-treated controls, EPO pre-treatment considerably reduced the ability of LPS 
to evoke hepcidin mRNA expression (LPS vs. EPO+LPS; P<0.001). However, the observed 
reduction was not absolute, because hepcidin levels remained higher in mice with the 
combined EPO and LPS treatments than in mice treated with EPO alone (EPO vs. EPO+LPS; 
P<0.0001). 
 
Hypoxia: Hypoxia has been identified as an independent regulator of iron absorption [373] and, 
consistently, exposure to hypoxia has been shown to suppress hepcidin mRNA both in mice in 
vivo and in isolated hepatocytes in vitro [363], suggesting that hypoxia may directly modulate 
hepcidin expression. To test whether hypoxia could, similarly to EPO, block LPS induction of 
hepcidin expression, mice were exposed to normobaric hypoxia (10% O2) for three days and 
received a single LPS injection 6 h before being analyzed. Hypoxia stimulated erythropoiesis, 
as judged by the elevation of hematological indices when compared to control, normoxic mice 
(RBCs – 23%; Hb – 21.8% and HCT – 23% increase). As expected [363], hypoxia alone led to 
suppression of hepcidin mRNA levels in the liver (~72% inhibition) but unlike EPO, was 
insufficient to block induction by LPS (~112% induction compared to control, normoxic mice, 
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Figure 2B).  
 
Erythropoietin inhibits LPS-mediated hepcidin induction independently of IL-6 
production  
LPS injection leads to the production of inflammatory cytokines, including IL-6 [374], which 
has been identified as a major hepcidin inducer [375]. Because EPO has been shown to inhibit 
LPS-induced secretion of IL-6 in cell lines [376], we next set out to determine whether the 
increase in IL-6 that occurs in vivo after LPS injection would be blocked in animals previously 
treated with EPO. We found that IL-6 mRNA as well as serum and intra-hepatic IL-6 levels 
were similar in mice treated with LPS alone and mice treated with both EPO and LPS (Figure 
3A-C). Furthermore, EPO treatment was able to completely inhibit IL-6-induced hepcidin 
expression (Figure 3D). These data reveal that in vivo, an IL-6-deficit is unlikely to explain 
EPO inhibition of hepcidin expression induced by LPS. 
  
Erythropoietin but not hypoxia partially inhibits phosphorylation of Stat3 mediated by 
LPS  
IL-6 production causes the activation of signal transducer and activator of transcription 3 
(STAT3) in hepatocytes which in turn
 
induces hepcidin [377, 378]. To analyze whether EPO 
would inhibit Stat3 activation by LPS in mice, we undertook phosphoimmunoblotting
 
of Stat3 
in liver nuclear extracts (Figure 4A) followed by chemiluminescence quantification and 
normalization to -actin as loading control (Figure 4B). We found that EPO treatment by itself 
reduced basal phosphorylation levels of Stat3 in the liver (P<0.01), whereas LPS induced both 
total Stat3 and its phosphorylation in the liver. Importantly, the phosphorylated Stat3/-actin 
ratio
 
was 54% lower in mice pretreated with EPO before LPS injection compared to animals 
treated with LPS alone.  
 
We similarly examined activation levels of Stat3 in hypoxic mice treated with LPS. As shown 
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in Figure 4C and 4D, hypoxia alone led to a reduction of basal Stat3 phosphorylation levels in 
the liver (P<0.01). However, unlike EPO, hypoxia was insufficient in influencing 
LPS-induced Stat3 activation. Taken together, these
 
data suggest that mechanistically, EPO 
pretreatment may result in deficits in LPS-induced Stat3-signaling
 
pathways without affecting 
IL-6 production.  
 
Erythropoietin but not hypoxia blocks hepcidin induction by dietary iron 
supplementation 
EPO: Next, we tested whether EPO treatment could similarly block the induction of hepcidin 
by iron, another well-established hepcidin inducer [362]. Mice were placed on a carbonyl-iron 
(CI)-supplemented diet, and treated with EPO for five days before being analyzed, as 
described in Materials and Methods. As expected, iron-loaded mice presented a 5.2-fold 
increase in liver iron concentrations compared to mice kept on the standard diet, reflecting a 
significant rise in iron stores (from 233±8 in control mice to 1,207±303 µg iron/g dry weight 
in iron-loaded mice; P<0.0001). Hepcidin elevation evoked by iron-loading was substantially 
blocked by EPO treatment (~86% inhibition, Figure 5A, CI vs. EPO+CI; P<0.001). However, 
as similarly observed with LPS, the reduction was not complete since hepcidin levels 
remained higher in mice with the combined EPO and CI treatments than in mice treated with 
EPO alone (EPO vs. EPO+CI; P<0.001).  
 
Hypoxia: To test whether hypoxia could also inhibit the induction of hepcidin expression in 
dietary iron-loading, mice were placed on an iron-enriched diet (2.5% CI) for two weeks. For 
combined treatment, the animals were simultaneously exposed to hypoxia for the last three 
days of the experiment. Again, feeding mice the iron-enriched diet led to a 5.5-fold increase in 
iron stores. As shown in Figure 5B, suppression of hepcidin mRNA levels by hypoxia was 
completely inhibited in iron-loaded mice, as hepcidin rose to similar levels as in mice exposed 
to the iron-enriched diet alone (2.7 and 2.4-fold induction, respectively).  
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Erythropoietin but not hypoxia inhibits phosphorylation of Smad1/5/8 mediated by iron 
Regulation of hepcidin expression by the iron-sensing pathway involves signaling through the 
bone morphogenetic protein and Sma- and Mad-related protein 4 (BMP/SMAD4) pathway 
that regulates hepcidin via  the Smad1, Smad5 and Smad8 set of Smad proteins [379]. To 
ascertain the potential role of this signaling pathway in the regulation of hepcidin by 
antagonistic stimuli, we examined the effects of dietary iron-loading on hepatic Smad1/5/8 
activation. As shown in Figure 6, iron-loading led to a 3-fold induction of phosphorylated 
Smad1/5/8 in the liver compared to basal levels in control mice. Most importantly, EPO 
treatment of iron-loaded mice completely inhibited this increase in Smad1/5/8 phosphorylation 
(Figures 6A and 6B). In contrast, activation levels of the SMAD4 pathway in hypoxic mice 
challenged with iron-loading were similar to those induced by dietary iron-loading alone, 
indicating that hypoxia is insufficient to block activation of the SMAD4 pathway by iron 
(Figures 6C and 6D). 
 
Suppression of hepcidin by the erythroid regulator depends on the degree of 
erythropoiesis activity  
While EPO significantly blocked hepcidin induction by LPS and dietary iron, this inhibitory 
effect was not total, as shown in Figures 2A and 5A. Furthermore, we observed that 
spleen/body weight ratio, as an indicator of extramedullary erythropoiesis activity, was 
significantly higher in mice treated with EPO than in hypoxic mice (Figure 7A). Because EPO 
production is also stimulated during hypoxia [380], we questioned whether dominance of the 
erythroid over the immune and stores regulator as opposed to hypoxia, depends on the extent 
of erythropoietic activity. To this end, we treated mice with increasing amounts of EPO for 
four days, from a total of 25 U (4x6.25 U) to 200 U (4x50 U), alone or in combination with 
LPS injections or with the CI-supplemented diet. We found a dose-like increase in the 
spleen/body weight ratio that was indistinguishable between mice treated with EPO alone and 
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mice treated with EPO in combination with LPS or CI (Figure 7B), indicating that discrete 
degrees of erythropoietic activity were attained in all treatment groups. Importantly, the 
capacity of EPO to block hepcidin induction by LPS or CI was strongly dependent on EPO 
dosage, with lower EPO dosages being significantly less effective in suppressing hepcidin 
expression compared to higher dosages (Figure 7C). The dose-dependent effect of 
erythropoietic activity on the inhibition of hepcidin in the presence of opposing stimuli was 
further supported by the strong inverse correlation of hepcidin mRNA concentration with the 
spleen/body weight ratio found in each treatment group (Figure 7 D-F; Spearman’s R=-0.747 
for EPO alone; R=-0.862 for EPO +LPS; and R=-0.815 for EPO + CI; P<0.0001), indicating 
that dominance of the erythroid regulator over inflammatory and store regulators depends on 
the degree of erythropoiesis activity. Finally, when both LPS and dietary iron treatments were 
combined to antagonize EPO-mediated hepcidin suppression, an additive effect of LPS and 
dietary iron counteracting EPO treatment was observed, with significantly higher hepcidin 
levels found in mice with the triple treatment, i.e. EPO, LPS and CI, compared to double 
treatments, i.e. mice treated with EPO + LPS or EPO + CI (P < 0.05; Figure 8). 
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Discussion 
Hepcidin has emerged as a central negative regulator of intestinal iron absorption and 
distribution that can be induced through at least two major pathways, namely, the 
inflammatory pathway and the iron-sensing pathway [381, 382]. In this study, we investigated 
its regulation through these two pathways in the presence of antagonistic stimuli. 
 
Inflammatory pathway: In the first set of experiments, we compared the capacity of 
erythropoietic drive stimulated by EPO and hypoxia to suppress hepcidin induction by 
inflammation, which was triggered by LPS injections in our model. Of note, LPS appears to be 
a relatively weak inflammatory stimulus in mice compared with other inflammatory 
conditions [363, 383], since in our experiments, it induced only a 2-fold increase in hepcidin 
mRNA levels. Even though our results show that hypoxia alone may be insufficient to inhibit 
hepcidin induction by LPS. In contrast, EPO led to inhibition of hepcidin induction by LPS, an 
effect that we found to be dependent on the degree of erythropoietic activity. The induction of 
hepcidin during inflammatory and infectious states can be mediated, at least in hepatocytes, by 
cytokines, mainly IL-6 [375], and subsequent STAT3 signaling. This pathway may be initiated 
by Toll-like receptor signaling leading to the induction of inflammatory cytokines 
[366],including IL-6, which binds to its membrane-bound receptor (gp80) on hepatocytes and 
interacts with gp130, resulting in Stat3 activation and binding to a regulatory element in the 
hepcidin promoter [212, 377, 378]. Recent studies have demonstrated that EPO potentially has 
anti-inflammatory properties for example, against brain injury [384], myocardial dysfunction
 
induced by ischemia/reperfusion [385] and chronic heart failure [386], and that EPO 
protection involves the suppression of inflammatory cytokines, including IL-6 [386, 387]. In 
our models, IL-6 production after LPS injection remained unaffected by EPO pretreatment, 
indicating that an IL-6 deficit is unlikely to explain EPO suppression of hepcidin in an 
inflammatory context. However, we found that EPO inhibits downstream signaling of both 
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basal and LPS-induced levels in the liver by suppressing Stat3 phosphorylation. To our 
knowledge, this is the first evidence that EPO might modulate hepatic hepcidin expression via 
suppression of STAT3 signaling in the liver in vivo. 
 
Iron-sensing pathway: In the second set of experiments, we evaluated the ability of hypoxia 
and EPO to block the up-regulation of hepcidin induced by dietary iron-loading, thus 
counteracting the iron-sensing pathway. We found that hypoxia was insufficient to block 
hepcidin up-regulation by iron. However, stimulation of erythropoiesis by EPO partially 
suppressed hepcidin expression in iron-loaded mice, indicating that the iron-sensing pathway 
can be blocked by erythropoietic drive.  
 
The iron-sensing pathway involves the activation of BMP/SMAD4 signaling, which is 
initiated after binding of BMP cytokines to BMP receptors, leading to the generation of 
phosphorylated RSmads, which dimerize with Smad4. The RSmad/Smad4 heterodimers 
translocate into the nucleus and presumably activate transcription of the hepcidin gene [379]. 
We found that dietary iron-loading in mice results in activation of the SMAD4 pathway, as 
judged by the induction of Smad1/5/8 phosphorylation. Similar results have been reported 
with parenteral iron challenge [214]. Importantly, we show that EPO pretreatment inhibits the 
activation of this pathway by iron, providing evidence that in vivo, EPO effects on hepcidin 
expression are mediated by the suppression of SMAD4 signaling.   
 
EPO has been shown to be able to modulate hepcidin expression directly in hepatocytes or 
indirectly through serum mediators. In fact, in vitro, EPO may directly suppress hepcidin 
expression in a dose-dependent
 
manner in the human hepatocyte cell line HepG2 [388]. In vivo, 
however, it has been demonstrated that during erythropoiesis stimulated by EPO, phlebotomy 
or phenylhydrazine, hepcidin suppression is blocked in mice in which erythropoiesis is 
simultaneously inhibited, indicating that the regulation of hepcidin by EPO is indirect and that 
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it requires increased erythropoiesis and possibly the release of some mediator(s) [389, 390]. 
Alternatively, EPO may interfere with signal transduction at the IL-6/gp80 receptor level and 
downstream signaling via gp130, which has been shown to be essential for hepcidin activation 
through STAT3 [212]. 
 
Dominance between regulators for hepcidin expression:  Recent studies in patients with 
thalassemia syndromes revealed that, despite elevated iron parameters present in patients with 
thalassemia intermedia, their urinary hepcidin levels are severely depressed, indicating that the 
erythropoietic drive may have a dominant effect over the iron signal [391, 392]. However, 
several confounding factors, including the effect of iron chelation, inflammatory conditions 
such as hepatitis C, presence or absence of splenectomy and the presence of iron-induced 
end-organ damage may render the assessment of the influence of opposing stimuli for hepcidin 
regulation more difficult in these patients [391]. In animal models, assessment of the influence 
of opposing signals for hepcidin expression has been performed by using only single dosages 
of the antagonistic stimuli. These experiments found that iron-loaded mice subjected to 
experimentally induced anemia showed reduced hepcidin expression [363], while 
iron-deficient mice injected with LPS up-regulated hepcidin expression [366], suggesting 
dominant effects of the erythroid and inflammatory regulators over iron stores. 
 
Our present results further advance those previous studies by showing that hepcidin expression 
levels in the presence of opposing signals, namely LPS and dietary iron, depend on the dosage 
of EPO used. Furthermore, we found that LPS and dietary iron can act additively to induce 
hepcidin in vivo, a finding that is in agreement with recently reported data of a synergistic 
induction of hepcidin expression by BMPs and IL-6 in vitro [393]. Taken together, these data 
indicate that final hepcidin levels are determined by the individual strength of the regulators 
rather than by an absolute hierarchy among the pathways. This notion is further supported by 
the finding that these effects are mediated, at least partially, through inhibition of STAT3 and 
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BMP/SMAD4 signaling in vivo, and thus offering an explanation as to how EPO suppression 
of hepcidin expression in the presence of antagonistic stimuli is dose-dependent. 
Dose-dependency also may explain why hypoxia seems to be unable to antagonize LPS or 
dietary iron, since much lower endogenous EPO levels are elicited by hypoxia compared with 
the high pharmacologic doses of EPO used in our experiments.  
 
In summary, the present data contribute to the elucidation of dominance among the regulators 
of hepcidin expression and provide insights into the mechanisms by which erythropoietic drive, 
stimulated by EPO, affects both inflammatory and iron-sensing pathways via suppression of 
STAT3 and SMAD4 signaling in vivo. 
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Figures and Legends 
 
 
 
 
Figure 1 Factors affecting mRNA hepcidin expression in the liver. Hepcidin levels are 
regulated by iron levels (store regulator), immune mediators (inflammatory regulator), 
hypoxia (hypoxia regulator) and erythropoietic demand (erythroid regulator). Pointed arrows 
indicate up-regulation of hepcidin and blunt arrows inhibition of its mRNA expression. For 
each regulator, the treatments used in this study to stimulate or suppress hepcidin expression 
are shown. 
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Figure 2 Erythropoietin but not hypoxia inhibits hepcidin induction through the 
inflammatory pathway.  (A) Hepcidin mRNA levels in the liver of mice treated with saline 
(control, CTL), erythropoietin (EPO), lipopolysaccharide (LPS) and mice with combined 
treatments (EPO+LPS). (B) Hepcidin mRNA levels in the liver of mice treated with saline 
(control, CTL), mice subjected to 10% oxygen (hypoxia, Hpx), LPS and mice with combined 
treatments (Hpx+LPS). Hepatic hepcidin expression was quantified by real-time RT-PCR and 
normalized to -actin. The hepcidin/-actin ratios are shown, each symbol representing 1 
mouse. Statistical analysis was performed by 1-way ANOVA; **P<0.001 for comparison with 
control mice. n.s. indicates not significant. 
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Figure 3 Erythropoietin inhibits LPS-mediated hepcidin induction independently of IL-6 
production. (A) IL-6 mRNA levels in liver, (B) IL-6 levels in serum, and  (C) Intra-hepatic 
IL-6 protein levels in mice treated with saline (control, CTL), erythropoietin (EPO), 
lipopolysaccharide (LPS), and mice with combined treatments (EPO+LPS). (D) Hepcidin 
mRNA levels in the liver of mice treated with saline (CTL), EPO, mouse recombinant IL-6 
(IL-6),, and mice with combined treatments (EPO+IL-6). IL-6 and hepcidin mRNA levels 
were quantified by real-time RT-PCR and normalized to -actin. The IL-6/-actin and 
hepcidin/-actin ratios are shown. IL-6 protein levels were measured by ELISA. Statistical 
analysis was performed by 1-way ANOVA; *P<0.01; and **P<0.001 for comparison with 
control mice. n.s. indicates not significant. Data are presented as means ± SD with n=6 mice 
per group in A, B and C and as individual mice in D.  
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Figure 4 Stat3 phosphorylation induced by LPS is partially inhibited by erythropoietin 
but not by hypoxia. (A and C) Liver nuclear extracts from mice treated with saline (control, 
CTL), erythropoietin (EPO), hypoxia, lipopolysaccharide (LPS) and mice with combined 
treatments (EPO+LPS and Hypoxia+LPS) were analyzed by Western blotting with an antibody 
to phosphorylated Stat3 and total Stat3. Blots were stripped and reprobed with an antibody to 
β-actin as loading control. A representative Western blot is shown. Lane “+” is a positive 
control consisting of total cell extracts from serum-starved HeLa cells prepared with 
interferon- treatment. (B and D) Quantification of chemiluminescence to calculate the ratio 
of phosphorylated Stat3 relative to β-actin (pStat3/β-actin). This experiment was repeated 
twice and the combined results are shown as means ± SD with n=7. Statistical analysis was 
performed by 1-way ANOVA; *P<0.01; **P<0.001; and ***P < 0.0001 for comparison with 
control mice. n.s. indicates not significant. 
 96 
 
 
 
Figure 5 Erythropoietin but not hypoxia inhibits hepcidin induction through the 
iron-sensing pathway.  (A) Hepcidin mRNA levels in the liver of mice treated with saline 
(control, CTL), erythropoietin (EPO), lipopolysaccharide (LPS), carbonyl iron supplemented 
diet (2.5%, CI) and mice with combined treatments (EPO+CI). (B) Hepcidin mRNA levels in 
the liver of mice treated with saline (control, CTL), mice subjected to 10% oxygen (hypoxia, 
Hpx), carbonyl iron supplemented diet (2.5%, CI) and mice with combined treatments 
(Hpx+CI). Hepatic hepcidin expression was quantified by real-time RT-PCR and normalized 
to -actin. The hepcidin/-actin ratios are shown, each symbol representing 1 mouse. 
Statistical analysis was performed by 1-way ANOVA; **P<0.001 for comparison with control 
mice. n.s. indicates not significant. 
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Figure 6 Smad1/5/8 phosphorylation induced by dietary iron-loading is partially 
inhibited by erythropoietin, but not by hypoxia. (A and C) Liver nuclear extracts from 
mice treated with saline (control, CTL), erythropoietin (EPO), carbonyl iron supplemented 
diet (2.5%, CI), hypoxia and mice with combined treatments (EPO+CI and Hypoxia+CI) were 
analyzed by Western blotting with an antibody to phosphorylated Smad1/5/8 and total 
Smad1/5/8. Blots were stripped and reprobed with an antibody to β-actin as loading control. A 
representative Western blot is shown. (B and D) Quantification of chemiluminescence to 
calculate the ratio of phosphorylated Smad1/5/8 relative to β-actin (pSmad/β-actin). This 
experiment was repeated twice and the combined results are shown as means ± SD with n=7. 
Statistical analysis was performed by 1-way ANOVA; *P<0.01; and **P<0.001 for 
comparison with control mice. n.s. indicates not significant. 
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Figure 7 Relationship between erythropoiesis rate and hepatic hepcidin expression. (A) 
Spleen weight/body weight ratio in control, hypoxic and EPO-treated mice (50U for 4 days). 
(B) Spleen weight/body weight ratio and (C) hepatic hepcidin expression in mice treated with 
increasing amounts of EPO (total dosage over four days is shown) alone (control - CTL) and 
in combination with LPS (LPS) or CI-supplemented diet (CI). (A, B and C) Data are 
presented as means ± SD with n=5-6 mice per group. Statistical analysis was performed by 
1-way ANOVA; *P<0.01, and **P<0.001 for comparison with control mice. (D, E and F) 
Negative correlation between spleen weight/body weight ratio and hepatic hepcidin expression 
in mice treated with increasing amounts of EPO: (D) alone (control - CTL) and in combination 
with (E) LPS (LPS) or  (F) CI-supplemented diet (CI). Hepatic hepcidin expression was 
quantified by real-time RT-PCR and normalized to -actin. The hepcidin/-actin ratios are 
shown.  
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Figure 8 Additive effect of LPS and dietary iron on EPO-mediated hepcidin suppression.  
Hepatic hepcidin expression in control mice (CTL), mice treated with EPO alone (50U for 4 
days; EPO) and in combination with LPS (EPO + LPS), with CI-supplemented diet (EPO + 
CI), with both LPS and CI (EPO + LPS + CI), with LPS alone (LPS) and CI-supplemented 
diet alone (CI). Data are presented as means ± SD with n=6 mice per group. Statistical 
analysis was performed by 1-way ANOVA; *P<0.05 for comparison with control mice. 
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Chapter 4 GENERAL DISCUSSION 
 
 
Iron and immunity are closely linked as many genes and proteins involved in iron metabolism 
also play a central role in controlling iron flux and preventing bacterial growth by limiting iron 
availability. Immune cells such as monocytes, macrophages, microglia and lymphocytes, via 
hepcidin-ferroportin regulation, can be resistant to bacterial invasion by regulating their iron 
levels and compartmentalization. The crosstalk between iron homeostasis and the immune 
system has long been studied. However, the molecular basis for their interaction remains 
poorly understood. Our studies concentrated on two molecules which are involved in both iron 
homeostasis and the immune response: lipocalin 2 and hepcidin. 
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Lipocalin 2 and other NTBI transporters 
 
Iron-overload diseases (e.g., thalassemia, HH) are characterized by the appearance in the 
plasma of NTBI that significantly contributes to iron accumulation in the liver, pancreas, and 
heart. The identification of the components of NTBI delivery pathway(s) will therefore 
provide novel targets for therapeutics. Initially, the innate immune molecule Lcn2 was 
demonstrated to bind bacterial siderophores, and as such, Lcn2 can impair microbial iron 
acquisition through iron sequestration, hence contributing to limiting bacterial infection.  
Several studies indicated that Lcn2, once bound to iron-loaded siderophores, might 
additionally exert an iron trafficking function. Therefore, in our study, we selected Lcn2 as a 
candidate involved in NTBI uptake in iron overload conditions. More precisely, we 
investigated whether Lcn2, as a component of an alternative iron delivery system, may 
contribute to the pathophysiology of HH. For this purpose, we induced and characterized iron 
overload in HfeLcn2 double knockout mice. We found that basal iron status and iron 
metabolism changes induced by dietary iron supplementation were indistinguishable between 
Hfe single knockout and HfeLcn2 double knockout mice. Our results thus indicate that Lcn2 is 
dispensable for NTBI uptake by hepatocytes in HH. However, they do not exclude that 
Lcn2-mediated iron delivery may be involved in other pathologies. For example, it has been 
reported that enteric infection with Salmonella Typhimurium results in luminal accumulation 
of Lcn2 and that microbial resistance to Lcn2 defines a specific adaptation of Salmonella 
Typhimurium to growth in the inflamed intestine [394, 395]. Nairz, M., et al reported that mice 
lacking one or both Hfe alleles are protected from Salmonella Typhimurium septicemia, with 
prolonged survival and improved control over bacterial replication. Importantly, this resistance 
was related to increased production of Lcn2 and consequent reduction of iron availability to 
Salmonella within Hfe-deficient macrophages [396].  
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Additional studies on other NTBI candidate transporters in iron overload diseases include Zrt- 
and Irt-like protein-14 (Zip14) [397],  and L-type voltage-gated calcium channels (LVDCCs). 
Zip14 is abundantly expressed at the major sites of organ damage in iron overload, namely in 
the liver, heart, and pancreas [398]. Overexpression of Zip14 in embryonic kidney (HEK) 293, 
SF9, or HeLa cell lines stimulates NTBI uptake [41, 399], while conversely NTBI uptake is 
inhibited when endogenous Zip14 expression is suppressed in AML12 mouse hepatocytes by 
small interfering RNA (siRNA) [41].  In a recent study, researchers expressed mouse Zip14 
in oocytes and found that the uptake of 
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Fe in the presence of L-ascorbate was enhanced, 
indicating that Zip14 is an iron transporter for ferrous iron (Fe
2+
) [400]. LVDCCs belong to a 
group of voltage-gated ion channels found in excitable cells (e.g., muscle, glial cells neurons, 
etc.) with permeability to Ca
2+
 ions [401]. In iron overload conditions, LVDCCs have been 
found to function as an iron transporter carrier of NTBI into cardiomyocytes and neuronal 
cells. Accordingly, LVDCC blockers were shown to be protective and able to attenuate 
myocardial iron accumulation in iron-overloaded mice. Recent studies also demonstrate a 
similar protective role of LVDCC blockers in neuronal cells, especially those neuronal cells 
highly sensitive to iron toxicity [402].  
 
The mechanism(s) of NTBI delivery are not only important for iron overload diseases and as 
such crucial for the understanding of the pathophysiology of these diseases, but also for iron 
delivery in the nervous system. The study of Pelizzoni L et al. showed astrocytes have the 
potential to buffer excess iron, thereby protecting neurons from iron overload [403]. Recent 
studies found that DMT-1 accounts for at least half of iron accumulation in the brain (mainly 
in astrocytes) [404]. Thus, DMT-1 mediates ascorbate-dependent ferrous iron uptake by 
astrocytes with the remaining NTBI uptake occurring via a DMT-1-independent route(s). 
DMT-1 may also participate in NTBI uptake in Schwann cells, which are responsible for the 
myelination of the peripheral nervous system (PNS). These findings suggest that iron may 
play a fundamental role in Schwann cell maturation and, as a consequence, in PNS 
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myelination [405], further highlighting the importance of identifying and characterizing the 
molecular players of NTBI cellular uptake systems. 
 
Hepcidin signaling pathway 
Hepcidin is the master regulatory hormone of systemic iron metabolism. It has emerged as a 
central negative regulator of intestinal iron absorption and distribution. Two major signaling 
pathways communicate systemic stimuli to induce hepcidin mRNA expression in hepatocytes, 
namely, the inflammatory and iron-sensing pathways [148, 406]. In our study, we investigated 
hepcidin regulation through these 2 pathways in the presence of antagonistic stimuli.  The 
study contributes to the elucidation of the dominance among the regulators of hepcidin 
expression, and in this regard we show that hepcidin expression levels are determined by the 
individual strength of opposing stimuli rather than by an absolute hierarchy among signaling 
pathways, as previously thought.  Similar conclusions were later reported by another group in 
rats [407].  In this study, rats were maintained on a standard or iron-deficient diet and were 
treated with LPS to induce inflammation, or with phenylhydrazine to stimulate erythropoiesis. 
The study found that the increase in hepatic hepcidin levels induced by LPS was not affected 
by phenylhydrazine treatment but was blunted by iron deficiency.  In addition, LPS-treated 
iron-deficient rats also showed lower hepatic inflammatory cytokine production, more 
specifically, IL-6 and TNF- production. Hence, these data further support the findings in our 
study that hepcidin expression levels are determined by the relative strengths of competing 
stimuli. On the other hand, the generalized effect of iron deficiency in LPS-treated animals 
regarding cytokine production additionally indicates that adequate iron levels are necessary for 
a full acute-phase response to take place. Yet another study performed by Catterall, W.A., et al. 
used rat models of iron deficiency anemia (IDA), anemia of chronic disease (ACD) and ACD 
with concomitant true IDA to investigate the expression of hepcidin as well as the activation 
status of upstream signalling pathways [408]. They found that SMAD1/5/8 phosphorylation 
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and hepcidin expression are activated in ACD, while in ACD/IDA SMAD1/5/8 
phosphorylation and hepcidin expression were suppressed. Furthermore, IDA resulted in 
reduced BMP6 expression and impaired SMAD1/5/8 phosphorylation, presumably effects 
related to the induction of the inhibitory factor SMAD7 and the reduction of the 
membrane-bound HJV. Altogether, their studies showed that, depending on the amount of 
body iron, inflammation-mediated stimulation of hepcidin expression could be blocked, again 
indicating that it is the strength of the opposing stimuli that determines the levels of hepcidin 
expression. 
 
A lasting question in our study is how EPO-induced erythropoiesis suppresses both the 
inflammatory and iron-sensing pathways. Our study showed that the effect of erythropoiesis 
could be partially blunted by iron overload. In this regard, erythropoietic alterations have been 
documented in iron overload situations, mostly in HH. These include increases in Hb levels, 
reticulocyte counts, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) [409-411] and 
most likely confirm the close relationship between iron availability for erythropoiesis and 
erythroid parameters.  Interestingly, several binding sites for the erythroid transcription factor 
GATA-1 are found in the HFE promoter, which indicates a possible role for HFE in 
erythropoiesis [412].  In fact, a recent study investigated the possible involvement of HFE in 
erythropoiesis using Hfe-deficient mice [413]. It was found that Hfe-KO mice respond better 
than wild-type mice to different erythropoietic stress conditions, which could be explained by 
two distinct, but non-exclusive, mechanisms: 1. Enhanced iron mobilization driven by 
deficient hepcidin response in Hfe-deficient mice; and 2. Enhanced Tf-bound iron uptake by 
erythroid cells, since the authors found that HFE inhibits Tf-iron uptake in erythroid cells. 
Both mechanisms would ultimately contribute to the acceleration of recovery from 
erythropoietic stress observed in Hfe-deficient mice. 
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The involvement of HJV - a crucial component of the iron-sensing pathway during 
erythropoiesis - had also been studied using the Hjv-deficient mouse model.  Hjv
-/-
 mice 
treated with EPO showed a significant decrease in hepcidin expression, similar to that 
observed in Wt mice, suggesting that HJV is not an essential molecule for EPO-induced 
hepcidin down-regulation [414]. Another study by the same group revealed that hepatic HJV 
protein levels are not affected by iron status nor by EPO administration, once again implying 
that HJV is not an essential component for EPO-mediated hepcidin suppression [415]. Further 
studies focusing on TMPRSS6, a protease known to cleave HJV [206], also yield similar 
results. In both Wt, TMPRSS6 deficient and TMPRSS6/HJV deficient mice, hepcidin 
expression responds to EPO suppression [416]. More recently, the role of different 
components of the BMP6/SMAD4 signaling pathway have also been examined in the mouse 
model of chronic stimulated erythropoiesis with secondary iron-loading, using two distinct 
models: 1. The haemolytic agent phenylhydrazine; and 2. The -thalassaemia mouse model 
Hbbth3/+ [417]. Both models rendered similar results, in that SMAD1/5/8 phosphorylation 
and suppression of hepcidin in the liver are not associated to BMP6 induction. In other words, 
hepcidin suppression due to erythropoiesis demand is independent of BMP/SMAD4 signaling 
[415].  
 
The influence of erythropoiesis in iron metabolism is not only limited to the inhibition of 
hepcidin expression. In monolayers of human intestinal Caco-2 cells, EPO was shown to be 
able to induce the expression of apical DMT-1 and basolateral FPN1, hence enhancing iron 
transport across monolayers. Therefore, EPO not only functions as a strong inhibitor of 
hepcidin expression, but also directly acts on enterocytes to increase iron absorption [418].   
 
Historically, hepcidin inducers have been more rapidly identified, while molecular 
mechanisms of hepcidin suppression remained to be identified. This state of affairs changed in 
the last years with the identification of several hepcidin suppressors. For example, two 
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candidates have been recently identified as being involved in modulating hepcidin suppression 
in response to increased erythropoietic activity, namely growth differentiation factor-15 
(GDF-15) and twisted gastrulation 1 (TWSG1) [161, 162], while SMAD7 has been identified 
as a general hepcidin suppressor using high throughput siRNA screening [419].  SMAD7 is 
an inhibitory SMAD protein that blocks TGF-β and BMP signaling through a negative 
feedback loop. Further studies showed that SMAD7 is co-regulated with hepcidin by BMPs in 
primary murine hepatocytes and that SMAD7 overexpression completely abolishes hepcidin 
activation by BMPs and TGF- In support of such a role, a distinct SMAD regulatory motif 
within the hepcidin promoter has also been identified, and this motif was shown to be involved 
in SMAD7-dependent hepcidin suppression. Heparin, another molecule used at pharmacologic 
concentrations, was found to strongly inhibit hepcidin expression in hepatic HepG2 cells. This 
inhibition was associated to sequestration of BMP6 and blocking of SMAD4 signaling [420]. 
Further evidence that heparin is a hepcidin modulator was provided by the observation that 
administration of heparin to prevent deep vein thrombosis in 5 patients was accompanied by a 
strong reduction of serum hepcidin and an increase of serum iron, presumably as a 
consequence of lower hepcidin levels favoring the release of iron into the circulation [420].  
 
An important aspect of hepcidin regulation that is not yet fully understood is how hypoxia 
suppresses hepcidin expression. Is it secondary to increased erythropoiesis driven by 
hypoxia-stimulated EPO or to a more direct effect of hypoxia on hepcidin expression? The 
answer to this question remains controversial. Several lines of evidence support the possibility 
that hypoxia induces hepcidin suppression through EPO stimulation, as EPO administration 
leads to reduced circulating hepcidin levels in humans [157] and to reduced hepcidin gene 
expression in mice [158, 421]; direct treatment of HepG2 cells with EPO causes a suppression 
in hepcidin expression [422].  More recent studies revealed that hypoxia-inducible factor-2 
(HIF2) is not required for hepcidin suppression under the conditions of an adaptive response to 
IDA [168]. Liu Q et al group generated a mouse model that dissociates Hif activation from 
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Epo synthesis. They found that hypoxia/Hif-mediated suppression of the hepcidin gene 
(Hamp1) happens indirectly through stimulation of EPO-induced erythropoiesis [169]. On the 
other hand, some available evidence supports a direct effect of hypoxia on hepcidin 
suppression. For example, HIF-recognition elements have been identified in the promoter 
region of the murine hepcidin gene and binding of HIF-1 was shown to negatively 
transactivate the hepcidin promoter [167]. Accordingly, hepatic HIF-1 inactivation leads to 
blunted hepcidin suppression in conditions of iron deficiency [167]. More recently, studies 
involving von Hippel Lindau (VHL) protein further indicate a direct role for hypoxia in 
regulating hepcidin. In humans, VHL
R200W
 homozygosity, which is common in Chuvashia, 
Russia, is characterized by elevated HIF-1 and HIF-2 levels, increased RBC counts, 
propensity for thrombosis, and early mortality [423]. In these patients, serum hepcidin levels 
were found to be negatively related to VHL
R200W
 homozygosity but not to serum EPO levels, 
hemoglobin, or RBC counts. These findings indicate that hypoxic responses leading to 
decreased expression of hepcidin may be independent of EPO levels and RBC counts [423].  
 
Parallel to these advances regarding the BMP6/SMAD4 signaling pathway for hepcidin 
expression, some breakthroughs have also been made regarding the inflammatory pathway, 
initiated by activation of JAK/STAT3 signaling. In fact, another cytokine belonging to the IL-6 
family of cytokines, named Oncostatin M (OsM), has been identified as a potent inducer of 
hepcidin, and this induction is also due to activation of the JAK/STAT signaling pathway 
[424].  
 
Hepcidin is mainly expressed in liver hepatocytes, and the signaling pathways discussed so far 
are pertinent to hepcidin production by these cells.  However, hepcidin is also expressed by 
macrophages [134-137]. In these cells, LPS and other bacterial components induce hepcidin 
through Toll-like receptor- (TLR) signaling [140]. The induction of hepcidin in macrophages 
results in iron retention in the macrophage by which the host reduces availability of iron from 
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pathogens and may promote host defense [136, 138]. These studies also indicate that autocrine 
regulation of iron accumulation in macrophages by hepcidin may affect the levels of 
proinflammatory cytokine production.  More recent studies in macrophage cell lines and 
primary peritoneal macrophages suggest that BMP4 or BMP6 can only induce hepcidin 
expression in macrophages if in the presence of LPS [139]. Accordingly, NF-kB inhibitors can 
abolish BMP/LPS-induction of hepcidin. These results show that in macrophages, unlike 
hepatocytes, BMPs regulate hepcidin expression in a LPS-NF-kB dependent manner, 
highlighting the close relationship between the iron-sensing and inflammatory pathways for 
hepcidin regulation.  
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Therapeutic applications of hepcidin 
Hepcidin plays a central role in iron metabolism, implying that both increased or decreased 
production of hepcidin potentially can contribute to the development of iron-related diseases. 
Therefore, targeting hepcidin as a means to appropriately regulating iron metabolism 
represents an attractive strategy for the treatment of iron-related diseases.  
 
Elevated hepcidin production is one of the pathophysiological mechanisms involved in the 
development of ACD. Reducing hepcidin production would thus augment iron bioavailability 
from the diet and from body iron stores to meet erythropoietic demand.  Presently, several 
strategies have been pursued to inhibit hepcidin production, including direct inhibition of 
hepcidin function, prevention of hepcidin transcription, and enhancing the resistance of 
ferroportin to hepcidin action.  
 
Direct inhibition of hepcidin function, such as anti-hepcidin antibodies, RNA interference 
(RNAi) and antisense oligonucleotides against hepcidin, hepcidin-binding proteins and 
hepcidin spiegelmers, have all been already tested for their ability to inhibit hepcidin function. 
For example, Ab12B9m, a humanized antihepcidin monoclonal antibody, with proven high 
affinity to human and monkey hepcidin, has been shown to block hepcidin action on 
ferroportin[425]. Most recently study with a mouse model of inflammation indicate that the 
mechanism of action of this antibody is due to an increase in available serum iron leading to 
enhanced red cell hemoglobinization [426]. The methods of mediating RNAi effect include 
small interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-functional shRNA. 
ShRNA directed at hepcidin have also been tested in mouse models to correct ACD [427]. 
However, RNAi approach is still a long way from achieving similar success in humans, as 
several obstacles must be bypassed, including effective designing of the RNAi  without 
off-target effects, stability of the RNAi in vivo, lack of biocompatibility of the delivery system, 
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and nonspecific targeted delivery to organs/cells [428]. In summary, antisense oligonucleotides 
either targeting hepcidin or hepcidin regulators are currently at the discovery stage of 
development.  
 
Another approach uses knowledge gained about anticalins, which are engineered lipocalins 
that have high affinity for targeted ligands and block their function [429]. A good example is 
provided by PRS-080, a recently developed anticalin that specifically targets human hepcidin. 
PRS-080 has been shown to effectively neutralize the development of short-term hypoferremia 
induced by injection of synthetic human hepcidin in mice [430]. Further studies are still under 
investigation.  
 
Last but not least, aptamers have also been investigated for their ability to inhibit hepcidin 
function. Aptamers are synthetic oligonucleic acid or peptide molecules that bind specific 
target molecules, and as such can be used to block the function of certain ligands [431]. As an 
example, NOX-H94 is a newly developed aptamer that binds to human hepcidin. Compared to 
other hepcidin antagonists, NOX-H94 has shown a high resistance to nuclease activity, good in 
vivo stability, and low immunogenicity [431, 432].  Since NOX-H94 was shown to 
effectively block hepcidin production in animal models, it has moved onto the clinical stage of 
testing [433].   
 
Other than directly targeting hepcidin, many research teams have focused on targeting the two 
major signaling pathways identified for hepcidin regulation, namely the BMP/SMAD4 and 
IL-6/STAT3 pathways. LDN-193189 is a potent inhibitor of BMP receptor Type I (ALK2 and 
ALK3) [434] that can inhibit excessive BMP signaling in vivo [435]. LDN-193189 can reverse 
anemia associated with streptococcal peptidoglycan-polysaccharide (PG-APS)-induced 
chronic arthritis in rats [436] and prevent acute inflammatory anemia induced by turpentine 
injections in mice [437]. However, LDN-193189 is not a specific inhibitor of the BMP/SMAD 
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pathway, and it can also block other pathways such as the MAPK/ERK pathway [438].   
 
Soluble HJV is known to negatively regulate the BMP/SMAD pathway. A soluble form of the 
human HJV protein linked to the constant region of IgG1 (HJV.Fc) has been proved to inhibit 
BMP-mediated hepcidin expression both in vitro and in vivo [185, 436].   
 
Anti-BMP6 monoclonal antibody is another option to inhibit BMP/SMAD pathway. It has 
been proven that anti-BMP6 antibody could effectively decrease hepcidin expression in both 
healthy and Hfe transgenic mice [187, 439]. However, the cross-reactivity of anti-BMP6 
antibody with other BMPs should be taken into consideration in the development of this 
therapeutic approach.  
 
The therapeutic strategy of inhibiting the IL-6/STAT3 pathway has mainly focused on 
blocking the IL-6 ligand/receptor and JAK/STAT3 signaling cascade. The anti-IL-6 receptor 
antibody (anti-IL-6R) Tocilizumab and anti-IL-6 chimeric monoclonal antibody, Siltuximab 
could effectively suppress hepcidin production in Multicentric Castleman’s Disease, a rare 
anemia associated with excessive production of IL-6 [440, 441]. The major issue of blockage 
of IL-6 activity is increasing the risk of infection [442, 443].  
 
The JAK2 inhibitor AG490 inhibits the phosphorylation of STAT3 by JAK2 and synthetic 
peptide inhibitor of STAT3 (PpYLKTK) disrupts pSTAT3 dimerization. In a mouse hepatic 
co-culture system, both compounds were able to inhibit STAT3 phosphorylation and thus 
decrease hepcidin production [444]. So far, these effects have not been tested in vivo. 
 
Hepcidin exerts its function through binding to and inducing the degradation of the iron export 
protein ferroportin. Thus, strategies that stabilize ferroportin on the cell surface are expected to 
exhibit the same effects as reducing hepcidin production. Cardiac glycosides are molecules 
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which were found by high-throughput screening approach that have been shown to prevent 
ferroportin internalization [445]. In addition, an anti-ferroportin mAb has been developed 
recently, which can block hepcidin-ferroportin interaction while maintaining ferroportin 
function. 
 
Current therapies for iron overload diseases (HH and β-thalassemia) are largely dependent on 
phlebotomy and iron chelation.  However, both options may have severe side effects and may 
not be well tolerated by all patients. The loss of hepcidin expression results in or contributes to 
iron overload in these disorders [446].  Therefore, it is rational to develop hepcidin 
replacement therapies to prevent and treat iron overload in these diseases.  Natural bioactive 
25 amino acid long hepcidin is limited by its high cost, short half-life and low absorption rate 
[447]. Recently, the Ganz’s group revealed that a thiol-disulfide interaction between 
ferroportin C326 and the hepcidin disulfide cage is essential to the stabilization of 
hepcidin-ferroportin binding [448]. Based on this, they developed several 7–9 N-terminal 
amino acids forms of hepcidin (minihepcidins) that include a single thiol cysteine, comprising 
the minimal structure that mimics hepcidin activity in both reporter cells and in mice [448]. 
They further developed an optimized minihepcidin (PR65) with superior potency, duration of 
action and reasonable costs. So far, PR65 has been tested in both iron-depleted and iron-loaded 
hepcidin knockout mice. The results indicate that PR65 could be beneficial for the prevention 
of iron overload or ameliorate the pre-existing iron overload [449].  The side effect is the 
dose-dependent iron-restrictive anemia from excess minihepcidin, which should be considered 
in future therapeutic applications.  
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Iron metabolism and immune system interaction 
A sophisticated network of cells and genes/proteins are involved in both the regulation of iron 
metabolism and defense against invading pathogens. Changes in iron homoeostasis, either iron 
deficiency or iron excess, may alter the ability of man to combat pathogen insult. On one hand, 
these alterations reflect the effects of iron on pathogen growth, and on the other, they may 
result from iron’s influence on the host response to the pathogen.  
 
Macrophages play important roles in both systemic iron homoeostasis and host defense. Iron 
content inside macrophages affect its ability of combating invading organisms. During the 
process of phagocytosis of foreign pathogens, NADPH oxidase, a multicomponent enzyme, 
generates superoxide inside the phagolysosome, and subsequently, produces Fe
2+
-catalysed 
hydroxyl radicals, which perform the function of phagocytic microbial killing. Iron levels 
inside macrophages affect the activity of NADPH oxidase, as iron depletion decreases while 
iron loading increases its activity [450]. Iron levels inside macrophages also influence the 
production of inducible nitric oxide synthase (iNOS), which is related to the cytotoxicity of 
macrophages. Iron loading suppresses while conversely, iron depletion enhances iNOS activity 
[450]. Microbial survival is related to macrophage iron content [228]. Iron-deficient 
macrophages, as seen in HH, have a lower susceptibility to bacterial infection. In contrast, iron 
overloaded macrophages, as seen in -thalassemia, have higher susceptibility to bacterial 
infections [451]. The outcome of intracellular pathogens, whether growth or destruction, is 
dependent on the iron content inside phagosomes. Nramp1 is a phagosomal iron transporter, 
which transports iron from phagosomes to the cytosol thereby suppressing the growth of 
intra-phagosomal pathogens. Hence, inactive Nramp1 results in uncontrolled growth of certain 
pathogens which was related to increased mortality [451]. Several studies have shown, both in 
vivo and in vitro, that infected macrophages release more hepcidin. Hepcidin, in this case, may 
function in an autocrine fashion to modulate local antimicrobial activity and inhibit iron 
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released from adjacent macrophages [135, 137].  
 
In general, iron deficiency may result in the suppression of immunity and, in fact, iron 
deficient individuals are more susceptible to infections. This increased susceptibility to 
infections appears to be related to altered innate immunity, T cell-mediated and adaptive 
antibody responses, as well as reduced neutrophil function [452]. The outcome of iron 
deficiency is also affected by variations in baseline iron status, severity of deficiency and other 
existing nutritional problems [452].  Iron supplementation could correct immune defects in 
iron deficiency, as it reduces the rate of respiratory infections in infants [452]. However, iron 
supplementation, particularly in the tropics, can also have deleterious effects on susceptibility 
to malaria and tuberculosis malaria infection [452, 453].   
 
Iron overload, depending on the pathophysiological mechanism, has a different impact on 
immunity. In HH, iron is mostly deposited in parenchymal cells. In general, due to the low 
iron content in macrophages, there is no evident increase in susceptibility to infections. 
However, HFE-related hemochromatosis may predispose individuals to infection of certain 
rare pathogens, such as Yersinia enterocolitica and Vibrio vulnificus [454-456]. On the bright 
side, it is also associated with an attenuated inflammatory response to Salmonella infection 
[457]. Lowered intracellular iron levels in HFE-related hemochromatosis reduces the 
biosynthesis of proinflammatory cytokines such as IL-6 and TNF- which may be related to 
impaired TLR4 signaling [458]. Mice lacking one or both Hfe alleles are protected from 
septicemia with Salmonella Typhimurium, which is related to enhanced iron-capturing peptide 
and lipocalin 2 production, thereby reducing iron availability for Salmonella growth[396]. 
Thus, the high prevalence of genetic hemochromatosis may result from evolutionary 
advantages that enhance host resistance to systemic infections with Salmonella. In contrasy, 
infection is the most prevalent complication in thalassemic patients. In -thalassemia, iron is 
mostly deposited in reticuloendothelial cells, thus affecting normal phagocytosis by 
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macrophages and suppressing killer cell activity, thereby increasing susceptibility to infections 
[215].  
 
Overall, it is clear now that iron status affects immune system functions. As an essential 
nutrient to both mammalian cells and pathogens, iron has a direct effect on the growth and 
virulence of microbial pathogens. Alteration of iron status influences the immune response in 
multiple ways. The challenge for researchers is to study the impact of iron on lymphocyte 
biology and adaptive immunity, particularly effector T cell functions. Moreover, newly 
emerging cytokines and immunomodulators may be potential regulators of iron homeostasis 
that deserve more attention.  
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Concluding remarks 
Over the last ten years, the understanding of iron metabolism has dramatically increased due to 
the discovery of hepcidin and many other molecules that are involved in iron metabolism. Our 
studies contributed to the knowledge of the dominance between regulators of hepcidin 
expression. We demonstrated that final hepcidin levels are determined by the individual 
strength of the regulators rather than by an absolute hierarchy among the pathways. We 
excluded lipocalin 2 as an NTBI transporter in the context of HH. Via different mechanisms, 
both hepcidin and lipocalin 2 are able to sequester iron and both possess antimicrobial 
properties. Hepcidin has intrinsic defensin-like antibacterial activity and induces iron 
sequestration in macrophages while Lcn2 binds siderophores and interrupts 
enterochelin-specific iron acquisition by bacteria. Future directions inspired by these studies 
should include the investigation of the mechanisms for hepcidin regulation and the possible 
impact of other immune cells, such as NKT cells, on iron metabolism. Furthermore, exploring 
the interaction between the abnormalities of immune functions associated with disorders of 
iron homeostasis and the actual biochemical reactions affected by changes in cellular iron 
levels should also yield important information critical for the advancement of the field. 
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